Special feature of 1905 film network Before the Double Eleven, domestic fans had entered the carnival mode.On October 29th, 2020, at the 20th National Cinema Domestic New Film Promotion Conference, more than 500 people gathered in Hengdian, Zhejiang, including 51 cinemas, over 50 film investment companies, distributors and production representatives. China Film, Huaxia, Bona, Wanda, Huayi and other upstream production companies have collectively promoted more than 100 outstanding domestic new films (including co-productions).

According to the information such as the promotion film list and the preparatory film list released by major film and television companies, it is accumulated that 262 new films will have or are expected to land in the cinema market in 2021. Among them, 242 films were made in China, accounting for 92.37% of the total, and 20 films were co-productions.

Movie Channel Merging Media, together with 1905 Movie Network and M Big Data, released the "2021 Cinema Foresight Report", and made a comprehensive inventory of 262 new films from the perspectives of film types, themes, IP and production companies.

What secrets will this report tell the audience behind the new film?

New films: plot, animation and comedy account for the largest proportion.

262 new films to be released, what state the progress bar is in, is one of the most concerned issues for the audience.

Judging from the current shooting progress, after rough statistics, there are 68 films in the preparatory stage, 112 films in the shooting and production stage, and 68 films have been completed and finalized. The proportion of new films in the shooting and production stage is the largest, reaching 42.75% of the whole.

Among the films that have been booked, at the 20th National Cinema Domestic New Film Promotion Conference, three relay films were booked for the Spring Festival in 2021, which pushed the market sentiment to a climax. The three films just correspond to animation, comedy and plot types respectively, which is highly consistent with the portrait data of the new film types to be released.

After counting the main elements of 262 new films to be shown, it can be found that the film list types cover 26 categories. Among them, the number of films with plot elements is 101, accounting for 22.1%, ranking first in the film genre. Animation and comedy genre films followed closely, reaching 47 and 45 respectively, accounting for 17.9% and 17.1% of the total.

The number of new animated films ranks second, which is closely related to the national craze caused by high-quality domestic animated films such as, and so on. The comedy film has always been one of the evergreen films in the world.

In the top ten genre films, except for the above three, the number of new films about action, suspense, love, fantasy and crime is above 30. In recent years, these types of films have not run away from many box office dark horses and have a certain audience base.

With more new films being produced and finalized, China audiences will have more choices on the big screen in 2021. For cinema managers, these new films also indicate that cinema revenue has a basic guarantee.

New trend: the main melody melody is in full bloom.　

In recent years, with the right climate and the right people, the main melody blockbuster has become the new favorite of the market.

,,, etc., organically integrated the theme of the times with commercial value, achieving a double harvest of box office and word of mouth. Facts have proved that the main melody blockbuster skillfully integrated with commercial elements is easier to be digested and absorbed by the audience.

Among the new films to be released in 2021, the theme film is still an important part worthy of attention. Among these films, there are not only the 100th anniversary of the founding of the Party, but also the theme of resisting US aggression and aiding Korea, as well as red classic films.

In addition to reviewing history, many main melody films follow the pace of the times, praising China spirit and carrying forward patriotic feelings. For example, Shenzhou, which is the theme of manned spaceflight, Doctor China, which tells the story of China people’s war and epidemic, and China Flight Tester, which tells the story of China’s "test hero" Li Zhonghua, etc.

There are more realistic works based on real people and story prototypes. For example, the economic investigation film adapted from the "Fox Hunting Action" of the Ministry of Public Security, the story about the Jedi rescue of the frontier armed police, and the theme of getting rid of poverty.

Since the summer file in 2018, after the upsurge of realistic works was started, the strong sense of substitution and resonance of such works are more likely to give birth to box office dark horses and are more favored by capital. In 2021, the realistic works in the mainland film market are still at the peak of creation.

The market value of classic IP is reflected in many ways, such as sequels, adaptations and remakes. Among the 262 new films to be released, such as "manslaughter 2", etc., or will form a domestic series of films. Detective Chinatown 3, which will be released in the Spring Festival in 2021, has become one of the most concerned films in the sequel.

In addition, The Order of the Gods, which is based on the explosive mobile game IP, and The Blade of Wandering, which is based on the novel IP of Ghost Blowing Lights, remake the classic "Loyal Dog Eight Men" and other films with the same name, and it has been or is expected to be scheduled for 2021. Mature market awareness and broad audience base are important reasons why classic IP is popular in the market.

And Ne Zha have successively become explosions, which not only proves that the level of China’s film industry keeps pace with the times, but also sets off the creation fever of similar films.

At the 2020 China Science Fiction Conference held in early November, a set of data showed that under the leadership of The Wandering Earth, the total box office of domestic science fiction films reached 7,140.5 million in 2019, an increase of 212% compared with 2018. In the future, domestic sci-fi films such as "The Trilogy of Outer Space" directed by Chen Sicheng, supervised by Ning Hao and directed by Zhang Xiaobei will attract much attention from the market.

After the national cinemas resumed work in an orderly manner, the Opinions on Promoting the Development of Science Fiction Films jointly issued by the State Film Bureau and the China Association for Science and Technology strengthened the system construction of science fiction film production and personnel training from the policy level.

In terms of animated films, the new films to be released in the future are both young and adult. The series "Bears haunt", the permanent guest of the Spring Festival file, is the best choice for parents and children to watch movies. Adult-oriented animation, such as Phoenix and Nezha 2, adapted from classic fairy tales, shoulders the heavy responsibility of creating more glories for domestic animation.

It is worth mentioning that many domestic documentaries in the film list have international vision and production standards, and have certain box office potential. Directed by Jia Zhangke, after the world premiere of the special screening unit of the 70th Berlin International Film Festival, the audience gained online reputation. The first BRICS documentary film "Young People Without Borders" led by director Lu Chuan and the first water resource documentary "Zero Water Day" are all worthy of attention.

New mode: New and old film and television companies explore more cooperation modes.

The film and television circle has always been a vanity fair, and the participation of capital is indispensable behind many new films.

According to the current public information, a number of film and television production agencies have participated in the production and distribution of many new works. China Film Group, Huayi Brothers, WANDA CINEMAS and Enlight Media have exposed more than 20 reserved films respectively. By participating in the statistics of the number of projects, it is not difficult to find that the traditional film and television companies in the head are still in the leading echelon, and the new Internet film companies have grown into the backbone.

WANDA CINEMAS and Huayi Brothers, as the "big brothers" in the industry, give full play to the advantages of resource integration, not only participate in the production of Spring Festival blockbusters such as Detective Chinatown 3 and The Order of the Gods, but also actively arrange online film and television services such as online movies and online dramas, and actively explore more production modes and revenue channels.

As representatives of Internet film companies, Alibaba Pictures, Cat’s Eye Film and Tencent Film have an average reserve of more than 15 films. In the past, the lack of master explosion movies has become a collective pain point for Internet film companies. Nowadays, with the resources and experience accumulated by deep participation in publicity and development, these companies are testing water more and more times.

In addition to the increasing number of master works, the types in the company’s film list are more and more diversified, and both commercial expression and author’s style are equally important, which has become one of the content characteristics of Internet film companies participating in film production. At the beginning of the announcement, these companies took advantage of big data and launched more new models.

There are more and more cases in which traditional film companies and Internet film companies strengthen cooperation and give full play to their respective advantages. For example, among the producers of 1921, Fox Hunting, and other films, there are both traditional and Internet studios. In addition, new cross-border forces, represented by POP MART cultural and creative companies, are increasingly appearing among new film investors.

In the creation of big-screen works, besides the blessing of capital, the participation of filmmakers is essential. Judging from the creative information of new films to be released in 2021, many heavyweight filmmakers are active in all aspects of film creation.

Among them, three directors, Ning Hao, Jia Zhangke and Wu Ershan, all participated in the creation of five films. Their identity, from director to producer to actor, can be described as omnipotent. The change of different identities can also see the help of mature directors for the younger generation.

Among these films to be released, M Big Data sorts out the ten works that are most expected by netizens. Among them, six films, such as Detective Chinatown 3, Japanese and Korean, have been booked for the Spring Festival in 2021.

Detective Chinatown 3 ranks first in the M-fever list of 8 works scheduled for the Spring Festival next year, followed by The Rescue and Boonie Bears:The Wild Life. According to previous market experience, Detective Chinatown 3, which has the highest popularity before the screening, will lead the box office competition for the Spring Festival. Whether this film can break the curse of "the front runner can’t be the total box office champion" is worthy of attention.

In the future, 262 new films will meet the audience one after another. The collective booking and release of these new films indicates that the China film market has recovered its former vitality and will create more glories.

　

Hang Zheng [2020] No.56

　

District and county (city) people’s governments, municipal government departments and directly affiliated units:

The measures for the basic medical security in Hangzhou are hereby printed and distributed to you, please follow them carefully.

Hangzhou Municipal People’s Government　　　

December 31, 2020　　　

　

Measures of Hangzhou Municipality on Basic Medical Security

　

Chapter I General Provisions

　

the first In order to further improve and perfect the basic medical security system in our city and safeguard the rights and interests of the insured, these measures are formulated according to the opinions and requirements of the Social Insurance Law of People’s Republic of China (PRC), the Regulations on Social Assistance in Zhejiang Province, and the national and provincial opinions and requirements on deepening the reform of the medical security system, combined with the actual situation in our city.

the second The basic medical security system adheres to the principles of universal coverage, overall planning of urban and rural areas, clear rights and responsibilities, fairness and moderation, multi-level sustainability, combination of fairness and efficiency, corresponding rights and obligations, and matching the level of security with the level of economic development.

Article Establish and improve a multi-level medical security system with basic medical insurance as the main body, serious illness insurance as the extension, medical assistance as the foundation, supplementary medical insurance, commercial health insurance and other common development. Specifically, it includes basic medical insurance for employees (hereinafter referred to as employee medical insurance), basic medical insurance for urban and rural residents (hereinafter referred to as urban and rural medical insurance), serious illness insurance and medical assistance system.

Article 4 These Measures shall apply to all employers and their employees, urban and rural residents, designated medical institutions for basic medical insurance, designated retail pharmacies (hereinafter referred to as designated medical institutions) and their regulatory agencies within the administrative area of Hangzhou.

Article 5 Hangzhou City [including Shangcheng District, Xiacheng District, Jianggan District, Gongshu District, Xihu District, Hangzhou High-tech Development Zone (Binjiang), Xiaoshan District, Yuhang District, Fuyang District, Lin ‘an District, Hangzhou Qiantang New District and Hangzhou West Lake Scenic Area], Tonglu County, Chun ‘an County and jiande city are respectively regarded as independent medical security management jurisdictions (hereinafter referred to as jurisdictions).

Article 6 People’s governments at all levels should incorporate medical security into the national economic and social development plan, implement laws, regulations, rules and policies on medical security, and provide organizational and financial support for medical security.

Article 7 The municipal medical security administrative department is in charge of the city’s basic medical security work. District and county (city) medical security administrative departments are responsible for the local basic medical security work, and medical security agencies at all levels (hereinafter referred to as medical insurance agencies) are responsible for the specific implementation.

Development and reform, economic and information, human resources and social security, agriculture and rural areas, health, civil affairs, finance, taxation, market supervision, education, auditing, public security, trade unions, disabled persons’ federations, veterans affairs, data resource management, statistics, women’s federations and other departments and units are responsible for medical security services and supervision and management within their respective functions and duties.

Article 8 In accordance with the principle of "policy, management, service, information and supervision", we will gradually implement the municipal overall planning of basic medical insurance. The city’s basic medical insurance fund shall be collected and accounted independently by each jurisdiction, and combined with the adjustment of management system, the city’s basic medical insurance fund shall be gradually realized.

Article 9 Each jurisdiction may, according to the local economic development level and the actual medical security, formulate regulations on medical treatment management in this jurisdiction in accordance with the requirements of county medical community construction and graded diagnosis and treatment.

Article 10 Establish and improve the social supervision organization of medical security, which is attended by representatives of government departments, insured persons, employers, trade unions and experts, analyze and master the operation of the medical security system, provide advice and suggestions on medical security work, and implement social supervision.

Chapter II Medical Insurance for Employees

　

Article 11 The following personnel within the administrative area of this Municipality shall participate in employee medical insurance within their respective jurisdictions:

(1) Employees of state organs, institutions, social organizations, various enterprises, private non-enterprises and individual industrial and commercial households (hereinafter referred to as employers) (including employers and employees, the same below);

(two) according to the relevant provisions of the one-time agreement to pay the basic medical insurance premium (hereinafter referred to as the co payment personnel);

(three) according to the provisions of these measures to enjoy the medical insurance retirement benefits of employees (hereinafter referred to as retirees);

(four) other personnel as prescribed by the state, province and city.

Article 12 Within the working age, the following urban and rural residents who are not employed by the employer can participate in the medical insurance for employees in this Municipality as flexible employees:

(a) the city’s household registration personnel can participate in the medical insurance for employees in the jurisdiction where the household registration belongs.

(2) Persons who are not registered in this Municipality, have terminated or terminated their labor relations with the employing unit, and the actual payment period of medical insurance for employees in this Municipality has accumulated for 10 years, and may participate in medical insurance for employees in their respective jurisdictions as required.

(three) other personnel as prescribed by the state, province and city.

Article 13 The employee medical insurance fee shall be paid by the employer and individual according to the following provisions:

(1) The employer takes the total wages of employees in the current month as the payment base (hereinafter referred to as the unit payment base), and pays the employee medical insurance (including maternity insurance) fee on a monthly basis, with the payment ratio of 9.9% (including the maternity insurance payment ratio of 0.4%).

When calculating the unit payment base, if the monthly salary of individual employees is higher than the average monthly salary of employees in all social units in Zhejiang Province last year (hereinafter referred to as the provincial flat salary), it shall be determined by 300% of the provincial flat salary last year; If it is less than 60%, it will be determined according to 60% of the provincial average wage in the previous year.

(2) On-the-job employees pay their medical insurance premiums at a rate of 2% based on their average monthly salary in the previous year, which is withheld and remitted by the employer on a monthly basis. If the average monthly salary of employees in the previous year is higher than the average wage in the previous year by 300%, the payment base shall be approved according to the average wage in the previous year; If it is less than 60%, the payment base shall be approved according to 60% of the provincial average wage in the previous year.

(three) in disabled soldiers, where the employees are retired for Grade 6 and above, individuals do not need to pay the employee medical insurance premium, and the employee medical insurance premium that the unit should pay is fully subsidized by the government.

(4) If an injured employee who is disabled at work and leaves the production post fails to terminate or terminate the labor relationship with the employer, the employer shall pay the employee’s medical insurance fee on a monthly basis based on the standard issued by his disability allowance until he receives the basic pension on a monthly basis; Workers with work-related injuries pay their medical insurance premiums at a rate of 2% based on their disability allowance, which is withheld and remitted by the employer on a monthly basis.

(five) 60% of the annual average wage of flexible employees is the payment base, and the employee medical insurance premium is paid monthly at the rate of 9.5%. Persons who hold the Certificate of Assistance and Support for Poor Persons, the Certificate of Minimum Living Security for Families, the Certificate of Minimum Living Security for Marginal Families, the Certificate of Basic Living Security for the Disabled or the People’s Republic of China (PRC) Disabled Persons’ Certificate of Grade II or above (hereinafter referred to as the holders) issued by the Civil Affairs and Disabled Persons’ Federation departments within the validity period shall be subsidized by the government for their employees’ medical insurance fees from the month when the medical insurance agency handles the registration formalities of relevant documents. Among them, those who hold the "Minimum Living Security Marginal Family Certificate" are subsidized by the government for half of the employee medical insurance premiums that individuals should pay, and other holders are fully subsidized by the government.

(six) during the period of receiving unemployment insurance benefits, the medical insurance premiums paid by the unemployed according to the payment standards of flexible employees shall be paid by the unemployment insurance fund.

(seven) the co-payment personnel shall pay the employee’s medical insurance fee in a lump sum when handling the co-payment procedures, and the specific standards shall be implemented in accordance with the relevant provisions of the municipal government.

During the period of re-employment, the employees’ medical insurance premiums shall be paid according to the standards of the employees.

According to the number of unemployed co-payers, the government subsidizes the employee medical insurance pooling fund according to the per capita standard of 2% of the provincial average wage in the previous year.

Article 14 Employers and individuals shall go through the formalities of insurance registration, alteration, cancellation and payment base declaration in a timely manner according to the regulations, and pay the medical insurance premiums of employees on time and in full.

Article 15 Persons who meet the conditions of insurance shall go through the formalities of insurance registration and payment declaration within 3 months after meeting the conditions, and enjoy the medical insurance benefits for employees from the next month after going through the formalities of insurance payment. Among them, the on-the-job employees shall be handled by the employer in a timely manner, and the employee medical insurance premium shall be paid as required.

The insured shall pay the employee’s medical insurance fee continuously until they enjoy the employee’s medical insurance retirement benefits. If the insured fails to pay the fee in the current month, the employee’s medical insurance benefits will be suspended from the next month. Unless otherwise specified, if retirees are suspended from medical insurance benefits for personal reasons, the medical expenses incurred during the suspension of medical insurance benefits will not be paid by the medical insurance fund.

Persons who receive unemployment insurance benefits shall enjoy medical insurance benefits for employees as required from the date of handling the medical insurance procedures for employees. The insured holder shall enjoy the relevant medical insurance benefits from the day when the medical insurance agency handles the registration formalities of relevant documents.

Article 16 Those who meet the conditions for participation in the insurance shall be deemed to have interrupted participation in the insurance if they fail to go through the procedures for participation in the insurance payment within the specified time period or continue to interrupt payment for 3 months or more. Interrupt the insured according to the following provisions:

(a) after the interruption of insurance for insurance procedures, should be continuous normal payment for 6 months, can enjoy medical insurance benefits for employees (hereinafter referred to as the waiting period). The medical expenses incurred during the interruption of insurance participation and the waiting period shall not be paid by the medical insurance fund.

(two) because the employer fails to handle the insurance registration formalities for the employees in time, which causes the employees to interrupt the insurance, the medical expenses incurred by the employees during the interruption of the insurance and the waiting period shall not be paid by the medical insurance fund.

If the employer fails to pay the employee’s medical insurance fee in accordance with the regulations after handling the insurance registration formalities for the employees, and all employees are interrupted to pay the fee, the employer shall repay it in accordance with the regulations; The employer shall, from the month following the full payment of the medical insurance premiums owed to employees, resume the medical insurance benefits of its employees, and the medical expenses incurred during the payment period shall not be paid by the medical insurance fund.

Article 17 The insured person may apply for the payment of the medical insurance premium of the employees during the insured period, according to the payment standards corresponding to different identities during the insured period, which shall be handled in accordance with the following provisions:

(a) to repay as an employee of the unit, the payment base of this year’s overdue period is determined according to my current payment base at the time of handling the overdue, and the payment base of previous years’ overdue period is determined according to the last year’s flat salary at the time of handling the overdue, and the payment ratio is 9.9% for the unit and 2% for the individual, and the starting time of overdue shall not be earlier than the time when my unit is included in the employee’s medical insurance coverage.

(2) If the payment is made as a flexible employee, it shall be implemented according to the payment standard of flexible employees at the time of payment, and the starting time of payment shall not be earlier than the year of payment procedures.

(three) the payment period is recorded as the actual payment period.

(four) the medical expenses incurred during the overdue period shall not be paid by the medical insurance fund.

(five) the medical insurance agency shall transfer the relevant funds corresponding to the payment according to the regulations; Replenish personal account funds and deduct serious illness insurance premiums that should be paid by individuals according to regulations.

Article 18 The following circumstances can be calculated as the employee’s medical insurance payment period, but not repeated calculation:

(a) the actual payment period of employee medical insurance.

(two) employee medical insurance is regarded as the payment period. In addition to the fixed number of years that employees’ medical insurance premiums should be paid according to the regulations, the basic old-age insurance for employees is calculated as the fixed number of years for employees’ medical insurance.

(three) before December 31, 2002 in line with the relevant provisions of the state and province of continuous service.

(four) the payment period for college students to participate in the medical insurance for urban and rural residents in Hangzhou (college students’ medical insurance).

(five) other years in accordance with the relevant provisions of the state and province.

Article 19 The actual payment period of medical insurance for employees in this Municipality includes the following three parts, but it is not repeated:

(a) the payment period of basic medical insurance for seriously ill employees in urban enterprises in this city;

(two) the actual payment period of participating in employee medical insurance in each jurisdiction of this Municipality and Zhejiang Province;

(three) the actual payment period of medical insurance in the army.

Article 20 When the insured person continues to pay the insurance premium in this city until he receives the basic pension or statutory retirement age on a monthly basis in this city, and the actual payment period of employee medical insurance in this city is over 10 years (inclusive), and the accumulated payment period of employee medical insurance is over 20 years (inclusive), he should enjoy the treatment of employee medical insurance retirees in accordance with the regulations after the medical insurance agency in the jurisdiction where he is insured handles the confirmation procedures of medical insurance retirement qualifications.

The following insured persons who fail to meet the requirements of the above-mentioned payment period and meet the requirements of laws, regulations and policies can choose to pay monthly or pay back the employee’s medical insurance premium for a specified period of time in the jurisdiction where they are insured, and enjoy the treatment of employees’ medical insurance retirees after going through the formalities for confirming their medical insurance retirement qualifications:

(a) the city’s household registration, continuous insurance payment in this city to receive basic pension or legal retirement age in this city on a monthly basis;

(2) Persons who are not registered in this Municipality, but who are employed by employers in this Municipality and who have continuously paid insurance premiums to the statutory retirement age, and who receive basic pensions on a monthly basis in this Municipality;

(three) people who are not registered in this city, but who have been continuously insured and paid to the statutory retirement age as flexible employees in this city.

Select the insured person who pays the employee’s medical insurance fee on a monthly basis, and the payment standard and medical insurance treatment shall be implemented according to the flexible employment standard in the same period; The insured person who chooses to pay the medical insurance premium for employees at one time shall be paid at the base of the last year’s provincial salary at the time of payment, and the payment rate shall be 9.5%. The medical insurance premium paid at one time shall not be included in the personal account. After choosing to pay the employee’s medical insurance premium at one time, it shall not be changed to pay the employee’s medical insurance premium on a monthly basis.

The certified personnel shall pay the required number of years on a monthly basis, and the part to be paid shall be subsidized by the government according to the regulations.

Article 21 Those who are not registered in this city, are not employed by employers in this city, and do not meet the insurance conditions for flexible employees in this city. After reaching the statutory retirement age, they will not enjoy the medical insurance retirement benefits for employees in this city.

Article 22 The personal account of the insured shall be established by the medical insurance agency in each jurisdiction according to the local conditions, and shall be uniformly managed according to the following provisions:

(1) Individual accounts shall be carried forward in a unified manner at the end of the settlement year, and the balance funds of individual accounts shall bear interest once according to the benchmark interest rate of bank demand deposits implemented on the day of carrying forward, and the interest generated shall be included in the funds of individual accounts over the years.

(two) when the annual carry-over, according to the category of personnel, age and the amount of payment or remittance, etc., the funds of the personal account for the next year are preset.

(III) For the newly insured or inter-annual renewal personnel within the year, the funds in their personal accounts in the current year are preset in the month when they go through the formalities of participating in (renewing) insurance, and the funds actually included are transferred from the employee’s medical insurance fee on a monthly basis from the month when the payment belongs.

(four) the balance of personal accounts in the current year, after the annual carry-over into the calendar year.

(5) If the insured person’s pre-set amount of funds in the current year is inconsistent with the actual amount of funds allocated in the current year due to cross-age and personnel category changes, adjustment of payment or debit amount, reimbursement of employee medical insurance fees, etc., the difference between the actual amount of funds allocated in the current year and the pre-set amount of funds in the current year will be included in the personal account of the following year when the annual transfer is made; The difference between the actual amount of funds transferred in the current year and the preset amount of funds in the current year is deducted from the current year’s funds in the personal account of the following year when the annual carry-over is made.

Article 23 The personal account funds of the insured are included in the following provisions:

(a) the funds in the personal account of employees in the current year are composed of two parts:

1. Employee medical insurance premiums paid by individuals.

2. Set the proportion by age group, and allocate the funds from the employee medical insurance fee on a monthly basis. Among them, urban insured persons under 45 years old (inclusive) are included in 0.5% of their base pay, and those over 45 years old before retirement are included in 0.8% of their base pay.

(two) the funds in the personal account of flexible employees in the current year shall be set according to the age group and included in the employee medical insurance fee on a monthly basis. Among them, those under 45 years old in urban areas are included in 0.5% of my base pay, and those over 45 years old before retirement are included in 0.8% of my base pay.

(III) The co-payment personnel shall pay 50% of the employee’s medical insurance premium in one lump sum when they go through the co-payment procedures, and transfer the funds from the employee’s medical insurance premium to their personal accounts in months during the co-payment period. If they are re-employed and participate in employee medical insurance, they will be included in their personal accounts for the current year.

(four) the funds of the retirees’ personal accounts in the current year shall be set according to the age group, and shall be included in the employee medical insurance fee on a monthly basis. Among them, the urban insured, I last year’s basic pension is lower than the previous year’s provincial average wage as the base, and I last year’s basic pension is higher than the previous year’s provincial average wage as the base. The proportion of debiting under 70 years old (inclusive) is 5.8%, and the proportion of debiting over 70 years old is 6.8%.

The personal account transfer standards in other jurisdictions can be implemented according to the original provisions before the national and provincial regulations on the reform of employee medical insurance personal accounts are clarified.

Article 24 The funds in the personal account in that year were used to pay the following expenses incurred by the insured:

(1) Medical expenses for general outpatient clinics (including emergency, the same below) that meet the scope of medical insurance expenses in designated medical institutions;

(2) Drug expenses that meet the scope of medical insurance expenses purchased at designated retail pharmacies;

(3) Expenses such as serious illness insurance premiums that should be paid by individuals.

Article 25 Personal account funds over the years can be used to pay the following expenses incurred by the insured:

(a) due to the need for diagnosis and treatment of diseases in designated medical institutions should be borne by individuals at their own expense, self-care, self-paid medical expenses;

(two) the use of preventive immunization vaccine fees in addition to the national expanded immunization program;

(three) the contract service fee for community responsible doctors that should be borne by individuals;

(four) other projects stipulated by the state and the province.

Article 26 The principal and interest of the personal account of the insured are owned by the individual, and can be transferred, liquidated and inherited according to the following provisions:

(a) after the termination or dissolution of the labor relationship between the insured and the employer, if the insured is insured in other overall plans, the transfer of the actual balance of funds in the personal account may be handled according to the regulations; Those who are not registered in this city and are not insured in other overall plans can handle personal account liquidation according to regulations.

(II) After the insured person is transferred from other insured places to the city, the actual balance of the personal account of the original insured place can be transferred to the city according to the regulations, and all of them will be included in the personal account funds over the years.

(III) If the insured transfers or liquidates his personal account for reasons such as the transfer of medical insurance, the cancellation of household registration after going abroad, death, etc., he must first settle the relevant medical expenses, and then transfer or return the actual balance of funds in his personal account according to regulations. Among them, if the personal account is overdrawn in the current year, it will be offset by the personal account funds over the years, and if the personal account funds are insufficient over the years, I will make up for it. The overdraft part of the personal account of the deceased in the current year shall be offset by the funds of the personal account over the years, and if the funds of the personal account are insufficient over the years, it shall be written off in the employee medical insurance pooling fund.

(four) personal account balance funds did not handle the transfer or liquidation procedures, once again to participate in the city’s medical insurance, can continue to use according to the provisions.

(five) after the death of the insured, the actual balance of funds in his personal account shall be handled by his legal heir or legatee at the medical insurance agency in accordance with the regulations.

(six) the personal account of the insured over the years, according to the provisions of the state and the province to help my close relatives (limited to spouses, children and parents) to participate in the basic medical insurance in this province. The mutual aid funds in accounts between the jurisdictions of this Municipality shall be liquidated regularly.

Article 27 In any of the following circumstances, the funds transferred to the personal account shall be stopped:

(1) Failing to pay or stop paying employee medical insurance premiums according to regulations;

(two) retirees have been stopped from issuing basic pensions;

(3) The insured person suspends or terminates medical insurance benefits due to sentence, death and other reasons;

(four) other circumstances stipulated by the administrative department of medical security.

Article 28 In a settlement year, the hospitalization medical expenses incurred by the insured in accordance with the scope of medical insurance expenses shall be settled according to the following provisions:

(1) The individual shall bear the medical expenses of one hospitalization Qifubiaozhun. For those hospitalized twice or more, the Qifubiaozhun shall be calculated according to the standard of the highest-level medical institution, specifically: tertiary and corresponding medical institutions (hereinafter referred to as tertiary medical institutions) in 800 yuan, other medical institutions (including secondary and corresponding medical institutions, the same below) in 500 yuan and community health service institutions in 300 yuan.

(two) the maximum hospitalization medical expenses paid by the employee medical insurance fund (based on the date of discharge, hereinafter referred to as the maximum hospitalization) is 400 thousand yuan.

(3) The hospitalization medical expenses above the hospitalization Qifubiaozhun and below the maximum hospitalization amount shall be shared by the employee medical insurance pooling fund and individuals. The employee medical insurance fund shall be settled according to the excess progressive system, and the specific proportion is:

1 hospitalization Qifubiaozhun above to 40 thousand yuan (inclusive), medical expenses incurred in tertiary medical institutions, 82% of employees, 86% of retirees; Medical expenses incurred in other medical institutions account for 84% of employees and 88% of retirees; The medical expenses incurred in community health service institutions account for 88% of employees and 92% of retirees.

24,000 yuan to 400,000 yuan (inclusive), medical expenses incurred in tertiary medical institutions, 88% of employees and 92% of retirees; Medical expenses incurred in other medical institutions, 90% of employees and 94% of retirees; Medical expenses incurred in community health service institutions account for 92% of employees and 96% of retirees.

Article 29 In a settlement year, the general outpatient medical expenses incurred by the insured in accordance with the scope of medical insurance expenses shall be settled according to the following provisions:

(a) first paid by the personal account in the current year, and if the personal account is insufficient to pay in the current year, the individual shall bear the medical expenses of an outpatient qifubiaozhun. Among them, the incumbent is 1000 yuan and the retiree is 300 yuan.

(2) The outpatient Qifubiaozhun of the year when the insured retires shall be calculated separately according to the actual months before and after medical insurance retirement, and then consolidated and determined. When the outpatient Qifubiaozhun actually paid by the individual in the year exceeds the payable part, the excess part will be included in his personal account over the years according to the proportion of 80%.

(3) The medical expenses above the outpatient Qifubiaozhun shall be shared by the employee medical insurance pooling fund and individuals, and the proportion borne by the employee medical insurance pooling fund is: 76% of the medical expenses incurred in tertiary medical institutions, and 82% of the employees and retirees; Medical expenses incurred in other medical institutions, 80% of employees and 86% of retirees; Medical expenses incurred in community health service institutions account for 86% of employees and 92% of retirees.

(four) the insured person who chooses the general practitioner to sign up for service, and who seeks medical treatment in the outpatient service of the contracted community health service institution, the proportion of the overall fund commitment shall be increased by 3 percentage points on the basis of the provisions of item (three) of this article.

(5) If the insured makes the first diagnosis in the contracted community health service institution, or is referred to other medical institutions for further treatment by the contracted community health service institution, the outpatient Qifubiaozhun shall be reduced or exempted in 300 yuan.

Chapter III Medical Insurance for Urban and Rural Residents

　

Article 30 Medical insurance for urban and rural residents is divided into children’s medical insurance, college students’ medical insurance and other urban and rural residents’ medical insurance:

(1) Children’s medical insurance coverage: children under the age of 18 who are registered in this Municipality, or students who have reached the age of 18 but are still studying in primary and secondary schools in this Municipality; Students who are not registered in this city, study in primary and secondary schools in this city, and one of their parents has participated in the medical insurance for employees in this city; Pre-school children (hereinafter referred to as children) who are not registered in this city, live in this city, and one of their parents has participated in the medical insurance for employees in this city and have paid a total of 3 years.

(II) College students’ medical insurance coverage: full-time undergraduate students, full-time graduate students and full-time students in technical colleges who have received general higher education in various full-time ordinary colleges and universities (including private colleges and universities) and scientific research institutes within the administrative area of Hangzhou (hereinafter referred to as college students).

(III) Coverage of medical insurance for other urban and rural residents: persons registered in this city and over 18 years old who have not participated in the basic medical insurance in this city or other places (hereinafter referred to as other urban and rural residents).

In addition to college students, people who meet the above conditions can participate in medical insurance for urban and rural residents in their respective jurisdictions. Among them, the city’s household registration should be insured in the jurisdiction where the household registration belongs, and those who are not registered in this city should be insured in the jurisdiction where they live.

Persons who are centrally adopted by social welfare institutions, children’s welfare institutions and other public welfare institutions within the administrative area of this Municipality (hereinafter referred to as adopters) shall be insured in their respective jurisdictions according to the above provisions.

Unless otherwise stipulated by the state, province and city, foreign students and foreign preschool children are not included in the scope of insurance.

Article 31 The financing standard of medical insurance for urban and rural residents is:

(1) Children’s medical insurance. 900 yuan per person per year, of which individuals pay 300 yuan and the government subsidizes 600 yuan.

(2) Medical insurance for college students. 270 yuan per person per year, of which individuals pay 90 yuan, and the financial subsidies at the same level are 180 yuan.

(three) other urban and rural residents’ medical insurance is divided into the following three financing standards:

1. The first grade of medical insurance for other urban and rural residents: 2,100 yuan per person per year, of which individuals pay 700 yuan and the government subsidizes 1,400 yuan.

2. Second grade medical insurance for other urban and rural residents: 1,800 yuan per person per year, of which individuals pay 600 yuan and the government subsidizes 1,200 yuan.

3. Third grade medical insurance for other urban and rural residents: 1,650 yuan per person per year, of which individuals pay 550 yuan and the government subsidizes 1,100 yuan.

Among them, other urban and rural residents can choose one or two files to pay for insurance; Other urban and rural residents in Tonglu County, Chun ‘an County and jiande city can choose to participate in the insurance within the grades approved by the local government.

Article 32 The medical insurance fee for urban and rural residents is raised annually, which consists of two parts: individual payment and financial subsidy. The amount of individual payment and the standard of government subsidy are not lower than the national and provincial regulations. The medical insurance fee for urban and rural residents that should be paid by the holder of the Minimum Living Security Marginal Family Certificate is subsidized by the government by half; Other certified personnel, adopters and entitled groups who enjoy regular pension subsidies should pay medical insurance fees in full by the government.

College students with certificates (including foreign household registration) shall enjoy government subsidies according to the provisions of the preceding paragraph, and the required funds shall be arranged by the finance at the same level according to the affiliation of colleges and universities.

Article 33 Establish a financing mechanism and a dynamic adjustment mechanism of financing standards that are compatible with the level of economic and social development and the affordability of all parties. In principle, the financing standard of medical insurance for urban and rural residents is adjusted every three years with an increase of not less than 10%, and the government subsidy standard and the proportion of individual contributions of urban and rural residents to the total financing are gradually increased. Specific by the municipal medical security, finance and taxation departments according to the city’s economic and social development level and fund operation research and approved by the municipal government to determine.

Article 34 Persons who meet the insurance conditions shall go through the insurance payment procedures in accordance with the regulations within 3 months after meeting the insurance conditions, and enjoy the medical insurance benefits for urban and rural residents in the remaining months of the settlement year from the next month after paying the medical insurance premiums for urban and rural residents. Among them, newborns who pay insurance within 3 months from the date of birth can enjoy the medical insurance benefits for urban and rural residents in the remaining months of the settlement year from the date of birth, but not earlier than the time when they meet the conditions for insurance.

Article 35 The insured shall go through the payment procedures for the next year’s participation (continuation) in accordance with the regulations. The specific starting and ending time of the participation (renewal) warranty period shall be subject to the announcement of the medical insurance agency in each jurisdiction in the current year. Insured persons enjoy medical insurance benefits for urban and rural residents in the settlement year to which the payment belongs.

Failing to go through the payment procedures for participation (renewal) within the specified time, it shall be regarded as interruption of participation. After the interruption of insurance, upon my own application, I can go through the payment procedures for participating (continuing) insurance in the current year, and I can enjoy the medical insurance benefits for urban and rural residents in the remaining months of the current year only after paying for 6 months.

Article 36 Children’s medical insurance and other urban and rural residents’ medical insurance insured persons can choose to pay medical insurance fees by banks or other means entrusted by the tax authorities after going through the insurance procedures.

Article 37 If the relevant information of the insured person changes, it shall go through the information change and confirmation procedures at the medical insurance agency in the jurisdiction in time.

Article 38 If a college student goes through the formalities of suspension from school due to illness or other reasons, he can continue to enjoy the medical insurance benefits for college students in accordance with the regulations during the suspension period.

If a college student is cancelled by a college, he/she will stop enjoying the medical insurance benefits for college students from the date when the college handles the cancellation procedures, and the medical insurance premiums paid by the individual for urban and rural residents will not be returned.

Article 39 In a settlement year, the hospitalization medical expenses incurred by the insured in accordance with the scope of medical insurance expenses shall be settled according to the following provisions:

(1) The individual shall bear the medical expenses of one hospitalization Qifubiaozhun. For those hospitalized twice or more, the Qifubiaozhun shall be calculated according to the standard of the highest medical institution, specifically: 800 yuan, a tertiary medical institution, 500 yuan, other medical institutions, and 300 yuan, a community health service institution.

(two) the maximum hospitalization limit for urban and rural residents’ medical insurance paid by the overall fund is 300 thousand yuan.

(three) the medical expenses above the hospitalization Qifubiaozhun and below the maximum hospitalization amount shall be shared by the overall fund and the individual. The proportion of the overall fund is 70% for tertiary medical institutions, 75% for other medical institutions and 80% for community health service institutions.

Article 40 In a settlement year, the general outpatient medical expenses incurred by the insured in accordance with the scope of medical insurance expenses shall be settled according to the following provisions:

(a) the individual shall bear the outpatient Qifubiaozhun in 300 yuan.

(two) outpatient Qifubiaozhun above part of the medical expenses, shared by the overall fund and individuals, of which the overall fund to bear the proportion of:

1. Children’s medical insurance, college students’ medical insurance and other urban and rural residents’ medical insurance: 40% for tertiary medical institutions, 60% for other medical institutions and 70% for community health service institutions.

2. Other urban and rural residents’ second-class medical insurance participants: 30% in tertiary medical institutions, 50% in other medical institutions and 60% in community health service institutions.

3. Other urban and rural residents with third-grade medical insurance: 30% in tertiary medical institutions, 40% in other medical institutions and 60% in community health service institutions.

(3) When the children’s medical insurance and other urban and rural residents’ medical insurance insured who choose to be contracted by general practitioners seek medical treatment in the outpatient department of the community health service institution that they signed, the proportion of the overall fund commitment will be increased by 3 percentage points on the basis of the provisions in Item (2) of this article.

Insured children and other urban and rural residents in the contracted community health service institutions for the first time, or by the contracted community health service institutions referred to other medical institutions to continue treatment, outpatient medical insurance Qifubiaozhun relief in 300 yuan.

(4) The proportion of outpatient reimbursement and Qifubiaozhun for the insured college students who voluntarily choose to seek medical treatment in the outpatient department of the medical institution in the school designated by medical insurance shall be implemented with reference to the provisions of Item (3) of this article.

Chapter IV Serious illness insurance

　

Article 41 All personnel who participate in the medical insurance for employees and urban and rural residents in this Municipality shall also participate in the serious illness insurance and pay the serious illness insurance premium. The serious illness insurance premium consists of individual payment, medical insurance fee transfer and government subsidy, which is used to establish a serious illness insurance fund.

The annual fund-raising standard for the employee medical insurance insured’s serious illness insurance is 100 yuan, in which the individual pays 48 yuan, and the employee medical insurance fee is transferred to 52 yuan, and the part that the individual should pay is withheld from his personal account in the current year; The insured person who chooses to pay a one-time payment should also pay the serious illness insurance premium. The annual financing standard of medical insurance for urban and rural residents is 90 yuan, in which individuals pay 40 yuan, and the government subsidizes 50 yuan each year, and the part that individuals should pay is transferred from the medical insurance premiums paid by them. The annual fund-raising standard for college students’ medical insurance participants’ serious illness insurance is 20 yuan, which is transferred from the medical insurance premiums paid by them for urban and rural residents.

Serious illness insurance premiums are raised on an annual basis, and the financing standards remain unchanged in the same settlement year. Medical security and finance departments can adjust the financing standards in a timely manner according to the operation of the serious illness insurance fund according to the prescribed procedures.

Article 42 The following medical expenses incurred by the insured that meet the scope of payment of serious illness insurance (hereinafter referred to as the compliance expenses of serious illness insurance) shall be shared by the serious illness insurance fund and individuals:

(1) Medical expenses for hospitalization and outpatient service of specified diseases that are above the maximum hospitalization limit and meet the scope of medical insurance expenses;

(two) below the maximum amount of hospitalization, hospitalization borne by individuals according to the proportion and out-patient medical expenses (including Qifubiaozhun);

(three) the cost of special drugs for serious illness insurance in Zhejiang Province;

(four) the expenses of rare disease drugs borne by individuals after enjoying the protection treatment of rare disease drugs in Zhejiang Province;

(five) other medical expenses stipulated by the state and the province.

Article 43 The drug security for rare diseases shall be coordinated at the provincial level, and the required funds shall be transferred from the serious illness insurance fund to the Zhejiang Province drug security fund for rare diseases. Insured persons are required to enjoy the unified treatment of rare diseases in the province.

Article 44 The starting and ending time of the insured’s serious illness insurance benefits is the same as that of the basic medical insurance benefits. In a settlement year, the major illness insurance compliance expenses incurred by the insured shall be settled according to the following provisions:

(1) The individual shall bear a minimum payment standard, specifically: 7,500 yuan for certified personnel, 13,000 yuan for retirees and 25,000 yuan for other insured personnel.

(two) the maximum payment limit of the serious illness insurance fund is 600 thousand yuan.

(3) The expenses above Qifubiaozhun and below the maximum payment limit shall be settled according to the excess progressive system, and the proportion borne by the serious illness insurance fund shall be:

1. Holders: 80% of the minimum payment standard is above 100,000 yuan (inclusive), 85% is between 100,000 yuan and 200,000 yuan (inclusive), 90% is between 200,000 yuan and 400,000 yuan (inclusive), and 95% is above 400,000 yuan.

2. Non-certified personnel:

Employees participating in medical insurance: the minimum payment is 75% above 100,000 yuan (inclusive), 80% between 100,000 yuan and 200,000 yuan (inclusive), 85% between 200,000 yuan and 400,000 yuan (inclusive), and 90% above 400,000 yuan.

Urban and rural residents’ medical insurance participants: 70% of the minimum payment standard is above 100,000 yuan (inclusive), 75% is between 100,000 yuan and 200,000 yuan (inclusive), and 80% is above 200,000 yuan.

Article 45 According to the actual medical security work in this city, the serious illness insurance can be managed by the medical insurance agency, or entrusted by a qualified third-party professional organization.

Chapter V Medical Assistance

　

Article 46 Medical assistance funds shall be arranged by the government of the jurisdiction according to regulations. Among them, the municipal financial arrangements for medical assistance funds, urban [limited to Shangcheng District, Xiacheng District, Jianggan District, Gongshu District, Xihu District, Hangzhou High-tech Development Zone (Binjiang), Fuyang District, Hangzhou Qiantang New District, Hangzhou West Lake Scenic Area] should be borne by the financial part, by the municipal finance and district finance in accordance with the actual expenditure of medical assistance funds, each bear 50%, and the part borne by each district in the current year will be settled through the urban financial system; Xiaoshan District, Yuhang District and Lin ‘an District shall undertake it by themselves according to the current financial system.

Article 47 The object of medical assistance is the certified personnel who participate in the medical insurance for employees or urban and rural residents in this Municipality, and other people with special difficulties as stipulated by the people’s governments at or above the county level.

Article 48 The sources of funds for medical assistance include:

(a) the government arranges a certain amount of funds every year;

(2) Funds raised through social donations and other forms;

(3) Interest income.

Article 49 Within a settlement year, the medical expenses incurred by the medical assistance object in the designated medical institutions that meet the scope of medical insurance expenses, after deducting the basic medical insurance, serious illness insurance and other Medicaid, are included in the scope of medical assistance, and assistance is provided according to the following standards:

(a) the holder of the "certificate of assistance and support for poor people", and his personal medical expenses for general outpatient service, hospitalization and prescribed disease outpatient service shall be fully rescued.

(two) the minimum living guarantee family card, the basic living guarantee card for the disabled and the second-level and above People’s Republic of China (PRC) Disabled Card holders, whose personal commitment to hospitalization and outpatient medical expenses for prescribed diseases is 70%; General outpatient medical assistance 50%, the maximum is not more than 3000 yuan.

(three) the holder of the "minimum living security marginal family card", whose personal commitment to hospitalization and outpatient medical assistance for prescribed diseases 60%.

Article 50 Medical assistance methods:

(1) Immediate assistance. The medical expenses incurred by the relief object when seeking medical treatment and purchasing medicines in the designated medical institutions with direct online settlement are in line with the provisions of these measures, and can directly enjoy medical assistance when the medical expenses are settled.

(2) assistance after the event. If the medical expenses that meet the standards of assistance are not provided with immediate assistance, the medical insurance agency shall provide medical assistance when applying for reimbursement.

Article 51 Medical assistance funds included in the financial accounts management, separate accounting, earmarking. Medical insurance agencies at all levels are specifically responsible for the audit and payment of medical assistance funds.

Article 52 The information of certified personnel shall be provided by the civil affairs department and the Disabled Persons’ Federation department, and the data shall be timely and accurately shared with the medical insurance agency through the information platform, and the certified personnel shall enjoy medical assistance from the date when the medical insurance agency handles the registration formalities of relevant documents.

Article 53 Established by the municipal administrative department of medical security led, civil affairs, finance, health, trade unions and other departments to participate in the joint meeting system of medical assistance in the city, to study and solve the special situation and major issues in the medical assistance work in the city, the office is located in the municipal administrative department of medical security. All districts and counties (cities) can establish corresponding medical assistance mechanisms.

For those who have been given medical assistance or other kinds of assistance, there are still serious difficulties in seeking medical treatment, or those who have suffered from serious chronic diseases or major diseases and have encountered other sudden difficulties in seeking medical treatment, they can apply by individuals, and the medical insurance agency will review and report, and then give some assistance after the joint meeting of medical assistance has agreed to study.

Chapter VI Maternity Insurance

　

Article 54 In accordance with the relevant provisions of the state and province, maternity insurance and employee medical insurance are combined. The employees of the employing units within the administrative area of Hangzhou shall participate in maternity insurance at the same time when participating in employee medical insurance.

Article 55 Maternity insurance benefits include:

(1) Maternity allowance;

(2) Maternity medical expenses;

(three) family planning operation allowance;

(four) family planning medical expenses.

Article 56 Workers who enjoy maternity allowance and family planning operation allowance shall meet the following conditions at the same time:

(a) in line with the provisions of national, provincial and municipal conditions of birth or the implementation of family planning surgery;

(II) When an employee is undergoing a fertility or family planning operation, the employer has gone through the insurance registration formalities in this Municipality in accordance with the regulations, and paid the premium continuously (excluding the overdue payment) for 12 months.

Article 57 If a female worker meets the requirements of childbirth or family planning operation, the maternity medical expenses and family planning medical expenses shall be settled according to the provisions of employee medical insurance.

In accordance with the provisions of the state to participate in the basic medical insurance for unemployed spouses, flexible employees and urban and rural residents insured, their compliance with the provisions of the maternity medical expenses and family planning medical expenses into the basic medical insurance fund payment.

Article 58 The formula for calculating and distributing maternity allowance or family planning operation allowance for female employees is: accrued allowance = average monthly salary of employees of the employer in the previous year at the time of maternity or family planning operation ÷30× accrued days.

The average monthly salary of the employees of the employing unit in the previous year shall be determined by the medical insurance agency according to the total annual average monthly salary of the insured employees of the employing unit in December of last year divided by the corresponding number. The average monthly salary of employees in the newly established employer in the previous year was calculated by the medical insurance agency according to the average monthly salary of employees insured by the employer.

Article 59 The accrued days of maternity allowance and family planning operation allowance shall be implemented according to the following provisions:

(1) Maternity allowance:

In accordance with the provisions of the "Regulations on Population and Family Planning in Zhejiang Province", the maternity allowance is paid according to 128 days of maternity leave (including 30 days of incentive leave); In case of dystocia, maternity leave will be increased by 15 days; In case of multiple births, the maternity leave will be increased by 15 days for each additional baby.

Female employees who have miscarried after less than 4 months of pregnancy are entitled to maternity leave for 15 days; If you have a miscarriage after 4 months of pregnancy, you will enjoy maternity leave for 42 days.

(two) family planning operation allowance:

1. Placement of IUD is counted as 2 days;

2. Take the IUD for 1 day;

3. vasectomy is counted as 7 days;

4. Simple tubal ligation is counted as 21 days;

5. Postpartum tubal ligation is counted as 14 days.

Article 60 Maternity allowance and family planning operation allowance shall be applied to the medical insurance agency in the area by the employer before the end of the following year after delivery or operation. After the audit, the medical insurance agency will allocate it to the employer where the employee is located, and the employer will issue it to the employee in accordance with the relevant provisions of the Measures for Labor Protection of Female Employees in Zhejiang Province and the maternity insurance treatment items and standards stipulated in these Measures.

Chapter VII Management of Medical Settlement

　

Article 61 The unified implementation of the national and provincial basic medical insurance, industrial injury insurance and maternity insurance drug list, provincial basic medical insurance medical services, serious illness insurance special drug list and other relevant provisions of the state and province.

The municipal medical insurance agency is responsible for the maintenance and management of the catalogue according to the regulations. The designated medical institutions shall, according to the requirements of medical insurance agencies, do a good job in maintaining and updating the drug list, medical service items and disease names of their own units in a timely manner.

Article 62 Insured persons shall apply for medical insurance vouchers according to national, provincial and municipal regulations (including electronic certificate, the same below), and seek medical treatment and purchase medicines in designated medical institutions under their jurisdiction with valid medical vouchers. Designated medical institutions should be calibrated according to regulations, and truthfully record the diagnosis and treatment and drug distribution.

Article 63 Designated medical institutions should choose safe, effective and reasonably priced drugs for the insured, and master the dosage according to the condition and the following prescription management principles: the dosage of acute diseases should not exceed 3 days; Generally, the dosage of chronic diseases does not exceed 15 days; Diseases included in the outpatient management of diseases and chronic diseases stipulated by our city, as well as other long-term chronic diseases and hospitalized patients who need to take therapeutic drugs when they leave the hospital, do not exceed 1 month’s dosage.

Encourage the insured to see a doctor in primary medical institutions. According to the needs of the management of chronic diseases of the insured, the contracted doctors can appropriately relax the time limit for dispensing prescriptions for chronic diseases of the insured under the premise of ensuring safe medication, and can extend the dosage of medical insurance for chronic diseases to 12 weeks at most.

Article 64 Unless otherwise stipulated in the jurisdiction, the settlement of medical expenses shall be carried out in accordance with the following provisions:

(1) If the insured needs to use Class B drugs in the list of basic medical insurance drugs and Class B items in the list of medical service items due to illness, a certain proportion of expenses shall be borne by the individual first, and then included in the scope of medical insurance expenses. The specific proportion of individual commitment shall be implemented according to the provisions of the administrative department of medical security in Zhejiang Province.

(II) When it is really necessary for the insured to use drugs and medical services with a prescribed course of treatment and variety and quantity due to illness, the relevant expenses can be included in the scope of medical insurance expenses only after going through the filing formalities in the designated medical institutions for medical treatment or the medical insurance agencies under their jurisdiction.

(three) if the insured person really needs to be diagnosed and treated in the designated medical institutions outside the jurisdiction, the insured person shall go through the relevant filing procedures according to the provisions of the jurisdiction. The medical expenses incurred by self-treatment without filing shall be borne by the individual at first, and then settled according to the regulations of the jurisdiction.

(4) If the medical expenses incurred by the insured in the designated retail pharmacies in this Municipality or in the ambulance due to emergency and rescue meet the scope of medical insurance expenses, they shall be settled according to the proportion of the general outpatient service of other medical institutions.

(5) Insured persons can purchase medicines from the designated medical insurance retail pharmacies with the external prescriptions issued by medical practitioners in designated medical institutions and filed in the information system. The designated retail pharmacies should check the information of prescription filing, adjust medicines and settle expenses according to regulations.

(six) the settlement of hospitalization medical expenses of the insured person adopts the discharge settlement system, and the medical insurance benefits can be implemented according to the provisions of insurance coverage when the medical expenses are settled, and the medical expenses incurred during the interruption of treatment are not included in the scope of medical insurance expenses. Insured persons who have been hospitalized for one year (365 days) shall be settled once.

During the hospitalization of the insured, the general outpatient expenses shall not be reimbursed. If it is really necessary for outpatient treatment in other local designated medical institutions due to illness, it shall be subject to the consent of the local inpatient medical institution before going to other designated medical institutions for treatment. The medical expenses that meet the scope of medical insurance expenses shall be borne by the individual at first, and then included in the original hospitalization medical expenses according to the regulations.

(seven) the insured shall not be forced to ask for hospitalization or refuse to leave the hospital. Do not meet the hospitalization conditions and forced hospitalization, the medical expenses incurred are not included in the scope of medical insurance expenditure; Those who meet the discharge conditions and refuse to leave the hospital will stop accounting after issuing the discharge notice in the relevant designated medical institutions, and the medical expenses incurred will not be included in the scope of medical insurance expenses.

(eight) the holder can see a doctor in the relevant Huimin hospital, and enjoy the medical fee reduction and exemption treatment according to the relevant provisions.

(9) If the insured fails to settle the medical expenses in the designated medical institutions according to the provisions of medical insurance due to reasons other than his own, and it conforms to the relevant policies of medical and health services, he can go to the designated medical institutions with the original cost settlement to go through the procedures for re-settlement of medical expenses according to the provisions, and all designated medical institutions should support and cooperate according to the relevant provisions.

(ten) if the insured has abnormal medical treatment, during the investigation and handling, the medical insurance agency may limit the scope and quantity of the designated medical institutions for medical treatment settlement, or change the medical insurance settlement method.

Article 65 In the designated medical institutions directly connected to the network (including designated medical institutions for medical treatment in different provinces and provinces), the medical expenses and drug purchase fees paid by the insured individuals shall be settled by the insured directly with the designated medical institutions according to the regulations; The medical expenses that should be paid by the medical insurance fund shall be settled by the designated medical institutions and medical insurance agencies according to the regulations.

The medical expenses that should be paid by the medical insurance fund in the designated medical institutions that are not directly connected to the network, or the medical expenses that cannot be settled in the designated medical institutions that are directly connected to the network due to emergency and medical insurance network failure, shall be paid in full by the insured before the end of the next settlement year to the medical insurance agency in the jurisdiction according to the regulations.

If the insured is treated in an emergency in a non-designated medical institution, after the treatment, the medical expenses shall be settled by the medical insurance agency in the jurisdiction with the emergency certificate. Medical expenses incurred by non-emergency treatment in non-designated medical institutions at the place of medical treatment shall not be paid by the medical insurance fund.

Article 66 Insured persons suffering from chronic diseases who need to carry drugs for continuous treatment during going abroad (border) shall go through the filing formalities according to regulations. Designated medical institutions can determine the dosage according to the time limit for going abroad (border), but it shall not exceed 6 months at most. During the period of going abroad, the settlement of medical expenses of the insured person shall be suspended.

If the personnel going abroad (border) return to Hangzhou in advance during the filing period, they should go through the cancellation procedures for filing abroad (border) in time. After going abroad (territory) personnel return to China, the expenses of temporary diseases that occurred before going abroad (territory) for filing and cancellation procedures are paid in full by individuals, and the expenses that meet the scope of medical insurance expenses are settled according to regulations after 10% of the expenses are taken care of by individuals.

Article 67 Establish a record system for permanent residence in other places. The settlement of medical treatment for insured persons living in other places shall be implemented in accordance with the following provisions:

(a) the insured who has lived in the field for more than 3 months shall go through the formalities for filing the permanent residence in the field according to the regulations. Among them, flexible employees who are not registered in this city, employers of individual industrial and commercial households and their employees, children and children will not go through the formalities for filing permanent residence in other places.

(II) The medical expenses incurred by the insured in the designated medical institutions in the long-term residence after going through the filing procedures for long-term residence in other places can be directly settled through the provincial and inter-provincial medical treatment platforms. If it is really impossible to settle directly, the medical insurance agency in the jurisdiction shall settle in accordance with the regulations after being paid in full by the individual.

(three) the insured who has gone through the formalities of filing for permanent residence in other places shall not cancel the filing formalities until 3 months after the filing takes effect. After the entry into force of the filing procedures for permanent residence of the insured, if the insured temporarily returns to the jurisdiction and needs general outpatient service or medicine purchase due to illness, he shall go through the formalities for temporary medical treatment and medicine purchase in the jurisdiction. If the formalities are not completed in time, the temporary disease expenses that meet the scope of medical insurance expenses shall be implemented in accordance with the relevant provisions of Article 69 of these Measures for the insured who temporarily leaves the permanent residence for medical reimbursement.

Article 68 Insured persons suffering from difficult diseases can not be diagnosed after examination by the city’s tertiary and corresponding designated medical institutions, or there are no treatment conditions after diagnosis, and the designated medical institutions can put forward suggestions for diagnosis and treatment, and after filing according to regulations, they will go to the corresponding designated medical institutions outside the province for medical treatment and settle accounts according to regulations. Among them, the insured persons who live in the field for a long time should be referred by the local three-level designated medical institutions before they can be transferred to the designated medical institutions outside the province or municipality directly under the Central Government where they live for medical treatment and settled according to the regulations.

If the insured person swipes the card for settlement in the designated medical institution for medical treatment in different places across the province where the record is filed, it shall be settled according to the relevant provisions of the state, and if it fails to be settled by credit card, it shall be paid in full by the individual to the medical insurance agency in the jurisdiction according to the provisions. In other designated medical institutions for the record, the medical expenses that meet the scope of medical insurance expenses shall be settled by the individual after taking care of 10%.

Article 69 Unless otherwise stipulated in the jurisdiction, the medical settlement during the temporary outing of the insured shall be implemented in accordance with the following provisions:

(a) the medical expenses incurred in the designated medical institutions in the province that meet the scope of medical insurance expenses shall, in principle, be treated in the designated medical institutions in different places in the province with my medical certificate and settled according to the regulations; The medical expenses that cannot be directly settled shall be paid in full by the individual to the medical insurance agency in the jurisdiction for reimbursement, and the expenses that meet the scope of medical insurance expenses shall be settled by the individual after taking care of themselves for 10% first.

The medical expenses incurred by the insured persons who live in other places temporarily leave their permanent residence and seek medical treatment in designated medical institutions in other parts of the province where their permanent residence is located shall be paid in full by the individual to the medical insurance agency for reimbursement, and the expenses that meet the scope of medical insurance expenses shall be settled by the individual after taking care of themselves for 10% first.

(II) During the temporary absence of the insured, the medical expenses incurred in the medical treatment in the designated medical institutions outside the province shall be paid in full by the individual to the medical insurance agency for reimbursement, and the expenses that meet the scope of medical insurance expenses shall be settled by the individual after taking care of himself for 20% first.

The medical expenses incurred by the insured persons who live in other places temporarily leave their permanent residence and go to designated medical institutions in other provinces and municipalities directly under the Central Government shall be paid in full by the individual and applied to the medical insurance agency for reimbursement. The expenses that meet the scope of medical insurance expenses shall be settled by the individual after taking care of themselves for 20%.

(III) College students can seek medical treatment in designated medical institutions in their relevant places of residence and practice during the winter and summer vacations, when they drop out of school due to illness, or during the internship period in accordance with the regulations of colleges and universities. The medical expenses incurred can be directly settled in local designated medical institutions by virtue of their medical treatment vouchers, or they can be paid in full by individuals to medical insurance agencies in accordance with the regulations.

Article 70 The prescribed diseases refer to various malignant tumors, systemic lupus erythematosus, hemophilia, aplastic anemia, childhood autism, schizophrenia, affective psychosis, AIDS and multidrug-resistant tuberculosis. Dialysis treatment of chronic renal failure and anti-rejection treatment after organ transplantation are included in the management scope of prescribed diseases. The scope of the prescribed diseases can be adjusted by the municipal medical security administrative department according to the actual situation, and promulgated and implemented after being approved by the municipal government. The medical security department should strengthen the supervision and management of prescribed diseases, and the specific measures shall be formulated separately.

The provisions of the insured medical treatment settlement according to the following provisions:

(a) patients with AIDS and MDR-TB are centrally accepted by the health departments in each jurisdiction, unified to the medical insurance agencies in the jurisdiction for filing procedures, and designated medical care is implemented.

(two) the insured with other prescribed diseases can handle the filing formalities according to the provisions with the relevant materials issued by the designated medical institutions at or above the second level in this Municipality. Among them, those who suffer from diseases such as schizophrenia, affective psychosis and childhood autism must hold relevant medical certificates issued by corresponding specialists in corresponding specialized hospitals or tertiary medical institutions.

(three) the establishment of outpatient medical security mechanism. The insured can enjoy the relevant treatment only after going through the prescribed disease filing procedures. In a settlement year, the outpatient medical expenses for the specified diseases of the insured shall be settled according to the hospitalization medical expenses, but there is no hospitalization Qifubiaozhun.

Article 71 Except as otherwise provided by the national, provincial and municipal medical insurance policies, the medical expenses incurred by the insured due to the following circumstances are not included in the payment scope of the medical insurance fund:

(a) outside the list of basic medical insurance drugs, the scope of medical services and the list of special drugs for serious illness insurance stipulated by the state and province;

(2) seeking medical treatment abroad;

(3) It shall be borne by a third party;

(four) shall be paid from the industrial injury insurance fund;

(five) should be borne by public health;

(six) other violations of the provisions of the basic medical security policy.

The medical expenses that should be borne by the third person according to law, but the third person fails to pay or cannot determine the third person, shall be paid in advance by the medical insurance fund. After paying in advance, the medical insurance agency has the right to recover from the third party.

Article 72 Insured persons who participate in basic medical insurance and commercial insurance at the same time shall settle accounts in advance according to the provisions of basic medical insurance. If commercial insurance is paid first, the paid medical expenses will be deducted at the time of medical insurance settlement.

Chapter VIII Public Management Services

　

Article 73 Persons who meet the conditions of insurance can only participate in one kind of basic medical insurance in the same period, but different types of insurance can be converted according to regulations, and the medical insurance premiums paid before the conversion will not be liquidated.

Insurance conversion refers to the insured changing the insurance coverage of employees’ medical insurance or urban and rural residents’ medical insurance for personal reasons, which shall be handled in accordance with the following provisions:

(a) other urban and rural residents during the medical insurance period, to participate in employee medical insurance as a flexible employee, continue to enjoy the medical insurance benefits of other urban and rural residents within 6 months of the normal payment of employee medical insurance, and enjoy the medical insurance benefits of employees after 6 months.

(two) to participate in the medical insurance for employees as flexible employees, and to participate in other urban and rural residents’ medical insurance, the insured month will continue to enjoy the medical insurance benefits for employees, and the next month will enjoy the medical insurance benefits for other urban and rural residents. If you want to participate in employee medical insurance again within 3 months, you can pay the employee medical insurance fee during this period, and enjoy the employee medical insurance benefits from the month after the payment.

(3) If the insured person changes insurance coverage after the original insurance coverage has been suspended for 3 months (inclusive), it shall be deemed that the insurance coverage has been interrupted, and the insured person shall enjoy the medical insurance treatment corresponding to the new insurance coverage after the new insurance coverage has been paid normally for 6 months.

After the natural termination of medical insurance benefits for urban and rural residents, those who continue to participate in employee medical insurance will still enjoy the medical insurance benefits for urban and rural residents who were originally insured in the same month and enjoy the medical insurance benefits for employees from the next month. After the natural termination of medical insurance benefits for urban and rural residents, those who continue to participate in medical insurance for urban and rural residents will enjoy the medical insurance benefits for newly insured urban and rural residents from the month of enrollment.

Article 74 The insured person who switches insurance types shall bear the outpatient Qifubiaozhun amount in a settlement year, which shall be determined according to the outpatient Qifubiaozhun corresponding to the medical insurance benefits he enjoys. If the amount of outpatient Qifubiaozhun that has been undertaken exceeds the converted insurance standard, it will not be liquidated.

Article 75 Insured persons who switch insurance types shall, when settling expenses in designated medical institutions, co-ordinate the fund allocation channels according to the provisions of the corresponding insurance types when enjoying treatment.

Article 76 If the insured person flows across the overall plan for employment, the transfer and connection procedures may be handled in accordance with the following provisions:

(1) A person who meets one of the following conditions may, when participating in employee medical insurance in this city, apply to the medical insurance agency in the jurisdiction for the transfer of medical insurance relationship, and transfer the payment period of employee medical insurance in the original insured place to the corresponding jurisdiction according to regulations:

1. Household registration personnel in this Municipality;

2. Non-local registered personnel, male under 50 years old and female under 40 years old;

3. Non-local household registration personnel have participated in the actual payment period of employee medical insurance in this city for a total of 10 years;

4. Personnel who are normally transferred with the approval of the organization department at or above the county level;

5 other personnel who meet the requirements of the state, province and city.

(two) the original insured employee medical insurance payment period can be calculated in accordance with the provisions of the cumulative transfer procedures to the month, but not with the actual payment period of employee medical insurance in this city.

(three) if the insured person flows across the city for employment, the city’s medical insurance should be suspended, and the employee’s medical insurance payment period should be transferred according to the regulations. Among them, if the insured fails to pay the employee’s medical insurance fee before the transfer of the medical insurance relationship, the transfer formalities can be handled only after the payment is made.

(four) the medical insurance relationship will not be transferred to those who have enjoyed the retirement benefits of medical insurance for employees.

Article 77 In accordance with the provisions of the transfer of medical insurance for urban and rural residents in other places who are transferred to the city to participate in employee medical insurance, they must continue to pay for 6 months before they can enjoy the medical insurance benefits for employees, and enjoy the medical insurance benefits for other urban and rural residents in the highest grade within their jurisdiction during the waiting period.

Article 78 Insured persons who have not gone through the medical insurance transfer and connection procedures, or have gone through the medical insurance transfer and connection procedures, but have not participated in the medical insurance for employees in other overall plans for 12 months before joining the insurance in this city, shall enjoy the medical insurance benefits for employees after they have paid the fees continuously for 6 months in this city.

Article 79 Non-local household registration personnel who are not employed by employers in this Municipality and do not meet the conditions for the participation of flexible employees should go through the formalities for transferring the medical insurance relationship in time.

Article 80 If the medical insurance relationship is transferred from outside the city, the outpatient and inpatient Qifubiaozhun and medical expenses paid in the original insured place will not be calculated cumulatively.

Before the actual medical insurance municipal co-ordination, if the insured area is converted within the city, the outpatient and inpatient Qifubiaozhun and medical expenses paid in the original insured area will not be calculated cumulatively.

Article 81 　Medical insurance agencies should establish and improve the corresponding business, finance, safety and risk management systems, and pay medical insurance benefits in full and on time.

Article 82 Medical insurance agencies can set up branches and service outlets within their jurisdiction according to the needs of their work, and provide efficient and convenient medical security public management services for employers and insured persons in accordance with the requirements of "running at most once" reform and government digital transformation; In accordance with the relevant provisions of medical insurance business file management, establish medical insurance files for employers and insured persons, completely and accurately record the personal information, payment and treatment enjoyment of insured persons and other medical insurance data, and properly keep the original vouchers for registration and declaration and accounting vouchers for payment and settlement.

Article 83 Employers and insured persons can handle medical security services through the information platform provided by the medical security department, inquire and check the records of their participation in insurance and medical security benefits, or require medical insurance agencies to provide medical security policy consultation and other related services.

Article 84 Medical insurance agencies for business handling, statistics, investigation and other needs, require relevant units and individuals to provide relevant medical insurance information, the relevant units and individuals shall provide timely and truthfully.

Medical insurance agencies and their staff shall keep the information of employers and individuals confidential according to law, and the information of employers’ business secrets, personal rights and interests, informants and complainants shall not be disclosed to others illegally.

Article 85 The medical insurance agency shall regularly announce to the public the operation of the medical insurance system and the income, expenditure and balance of the medical insurance fund.

Chapter IX Management of Medical Services

　

Article 86 The medical security department shall determine the scale and layout of designated medical institutions according to the operation of the medical insurance system and the balance of fund income and expenditure, combined with factors such as the allocation of regional medical and health resources and the medical needs of the insured, and the specific measures shall be formulated separately.

Article 87 Designated medical institutions implement agreement management. Eligible medical institutions apply voluntarily, and after the examination and evaluation by the medical security department and the signing of an agreement with the medical insurance agency, they provide medical services for the insured according to the principle of "treatment due to illness, reasonable examination, rational drug use and reasonable treatment", and implement the medical insurance payment policy, price policy and centralized procurement policy in accordance with the regulations.

Article 88 Unify the text of medical insurance agreement and the management operation process of medical insurance agreement in designated medical institutions in the city, and realize standardized and standardized management. Medical insurance agencies and designated medical institutions shall perform their respective rights and responsibilities according to the contents of the agreement. Any party who violates the service agreement shall bear the liability for breach of contract and deal with it according to the agreement.

Designated medical institutions suspected of violating the rules, during the investigation and handling, the medical insurance agency may suspend its settlement function or suspend the allocation of medical expenses.

Article 89 Medical security departments at all levels should do a good job in organizing the formulation and implementation of payment standards and charging policies for drugs, medical consumables and medical services in accordance with the prescribed authority, and establish a dynamic adjustment mechanism for medical service prices and a monitoring and information release system for medical service prices.

Article 90 Each jurisdiction should follow the principle of "fixed income and expenditure, balance income and expenditure, and have a slight balance", improve and perfect the multiple compound payment methods that combine DRGs point method, bed-based payment, head-to-head payment and project-based payment under the total budget management, effectively strengthen the management of medical expense settlement, and improve and improve the cost assessment and evaluation mechanism of designated medical institutions. The assessment results should be linked to the medical quality and performance of the agreement.

Article 91 Medical service practitioners in designated medical institutions shall provide scientific, standardized and reasonable medical services according to the needs of patients’ illness, strictly fulfill the contents of service agreements and abide by relevant regulations.

Article 92 Medical insurance agencies may set up medical insurance expert advisory committees, which are responsible for participating in professional consultation on difficult medical insurance issues and fixed-point evaluation of medical institutions. The working funds of the medical insurance expert advisory Committee are included in the budget of the medical security department.

Chapter X Fund Supervision and Management

Article 93 The sources of medical insurance fund include contributions from employers and individuals, government subsidies, deposit interest of the fund, donations from citizens, legal persons and other organizations and other income.

Article 94 Employees’ medical insurance premiums, urban and rural residents’ medical insurance premiums and serious illness insurance premiums shall be collected by the tax authorities, and the information on fee collection shall be provided to the medical security department and the financial department on a regular basis. Township people’s governments, sub-district offices and institutions of higher learning in Hangzhou should actively assist in the collection of medical insurance fees, and human resources and social security departments should cooperate with the unemployed to pay medical insurance fees according to regulations.

Article 95 The medical insurance fund shall be subject to budget management, incorporated into the financial special account, managed by two lines of revenue and expenditure, and earmarked for special purposes. No organization or individual may misappropriate, and the government shall give subsidies according to the operation of the medical insurance fund, specifically in accordance with the following provisions:

(a) when there is a deficit in the employee medical insurance fund in each jurisdiction, it shall be paid by the balance of the employee medical insurance fund in each jurisdiction over the years, and the insufficient part shall be shared by the financial and municipal employee medical insurance risk adjustment funds in each jurisdiction. Among them, the part of Hangzhou urban area [limited to Shangcheng District, Xiacheng District, Jianggan District, Gongshu District, Xihu District, Hangzhou High-tech Development Zone (Binjiang), Hangzhou Qiantang New District and Hangzhou West Lake Scenic Area] that should be borne by the finance shall be borne by the municipal finance and the district finance, 50% respectively; Xiaoshan District, Yuhang District, Fuyang District and Lin ‘an District shall bear their own responsibilities according to the current financial system.

(two) the area of urban and rural residents’ medical insurance fund (excluding college students’ medical insurance fund) deficit, first by the area of urban and rural residents’ medical insurance fund balance payment over the years, the insufficient part shall be borne by the jurisdiction of the financial. Among them, the part of Hangzhou urban area [limited to Shangcheng District, Xiacheng District, Jianggan District, Gongshu District, Xihu District, Hangzhou High-tech Development Zone (Binjiang), Hangzhou Qiantang New District and Hangzhou West Lake Scenic Area] that should be borne by the finance shall be borne by the municipal finance and the district finance respectively in proportion to the number of insured persons; Xiaoshan District, Yuhang District, Fuyang District and Lin ‘an District shall bear their own responsibilities according to the current financial system.

When there is a deficit in college students’ medical insurance fund, it shall be paid by the balance of college students’ medical insurance fund over the years, and the insufficient part shall be borne by the finance at the same level of colleges and universities according to the proportion of the number of participants in each college.

(three) when there is a deficit in the serious illness insurance fund, it shall be paid by the balance of the serious illness insurance fund in each jurisdiction over the years, and the insufficient part shall be borne by the finance of each jurisdiction.

Medical insurance agencies at all levels should do a good job in accounting and financial statistical analysis of medical insurance funds, establish corresponding financial management systems, and implement separate accounting for various medical insurance funds for special purposes.

Article 96 The municipal administrative department of medical security, the financial department and the auditing organ shall, in accordance with their respective duties, supervise, inspect and audit the income and expenditure, management and investment operation of the medical insurance fund. The bank interest of the medical insurance fund shall be calculated in accordance with the relevant provisions of the state.

Article 97 The establishment of municipal medical insurance risk adjustment system, the specific measures shall be formulated separately.

Article 98 The administrative department of medical security should formulate and improve the relevant regulations on the supervision of medical insurance funds, and standardize the supervision authority, procedures and punishment standards.

Establish a medical security credit system, and implement joint incentives for trustworthiness and joint punishment for dishonesty.

Article 99 The administrative department of medical security should establish a normal mechanism of supervision and inspection, and implement real-time dynamic intelligent supervision of big data. Gradually establish a medical insurance fund performance evaluation system, improve the evaluation mechanism of medical services, and implement performance management throughout the fund operation.

Article 100 Medical security departments at all levels shall, in conjunction with health, market supervision, public security and other departments, implement cross-departmental collaborative supervision and strengthen supervision, inspection and assessment of designated medical institutions. Actively introduce third-party supervision forces, strengthen social supervision, improve the reward system for fraudulent insurance reporting, and maintain the safe operation of medical insurance funds.

Article 101 Medical insurance agencies should implement effective supervision and implement the responsibility of agreement management, cost monitoring, audit and audit by building an intelligent medical insurance supervision platform and establishing system measures such as daily inspections, special inspections, key spot checks, online inspections, and entrusted third-party audit inspections.

Article 102 Medical insurance violations of employers, designated medical institutions, medical insurance agencies and their staff, insured persons and other personnel shall be handled in accordance with the Social Insurance Law of People’s Republic of China (PRC), Measures for Handling Violations of Basic Medical Security in Hangzhou and other relevant laws and regulations.

Chapter XI Supplementary Provisions

Article 103 The medical insurance funds mentioned in these Measures include employee medical insurance (including maternity insurance) funds, urban and rural residents’ medical insurance funds, serious illness insurance funds and medical assistance funds.

Article 104 The expense settlement year of employee medical insurance and urban and rural residents’ medical insurance is from January 1st to December 31st every year, and the expense settlement year of college students’ medical insurance is from September 1st to August 31st of the following year. The settlement year of the insured’s serious illness insurance and medical assistance is the same as the basic medical insurance types they participate in.

Article 105 Except as otherwise provided, foreigners who have obtained relevant employment certificates or foreigners’ residence certificates, permanent residence certificates, innovation and entrepreneurship visas and other entry and exit certificates in accordance with the law and are legally employed in this Municipality shall participate in employee medical insurance in accordance with these measures and enjoy the medical insurance benefits for employees.

Those who live in China but are not employed can participate in the basic medical insurance with reference to the provisions of the city’s household registration personnel with the "Permanent Residence Permit for Foreigners" issued by the public security department of this Municipality, and those who hold the "Permanent Residence Permit for Foreigners" issued by the public security department of this Municipality can participate in the basic medical insurance with reference to the provisions of the non-local household registration personnel.

Hong Kong, Macao and Taiwan compatriots who are legally employed in this Municipality or hold residence permits issued by the public security departments for Hong Kong, Macao and Taiwan residents shall refer to the provisions of the preceding two paragraphs.

Article 106 Old workers who participated in revolutionary work before the establishment of People’s Republic of China (PRC), retired six-level and above disabled soldiers, municipal and above high-level talents, municipal and above model workers, and those who enjoy medical treatment for model workers with reference, enjoy medical care on the basis of enjoying basic medical insurance benefits, and specific measures shall be formulated separately.

Article 107 The term "self-funded expenses" as mentioned in these Measures refers to medical expenses that do not meet the scope of medical insurance expenses; Self-care expenses refer to the scope of medical insurance expenses, but before settlement according to medical insurance regulations, a certain proportion of medical expenses must be borne by the insured; Out-of-pocket expenses refer to medical expenses (including Qifubiaozhun) that are in line with the scope of medical insurance expenses and should be borne by individuals in proportion according to regulations.

Article 108 If the original invoice for medical expenses has been used as the reimbursement voucher of the relevant department or unit, the relevant department or unit may issue the original voucher split sheet and affix the special financial seal, and then settle the account according to the relevant provisions.

Article 109 The relevant data such as the collection base of medical insurance fees for flexible employees in the next year shall be published by the municipal medical security administrative department and the municipal tax department before the end of each year.

Article 110 After the medical insurance benefits of the insured are started, the paid medical insurance fees will not be returned.

Article 111 The employer may establish supplementary medical insurance for employees to improve the level of medical security for employees, and the required funds shall be charged according to the relevant provisions of the state.

Article 112 Medical expenses caused by major public epidemics or large-scale natural disasters, as well as medical expenses exemption policies for specific groups and specific diseases, shall be implemented in accordance with relevant national and provincial regulations.

Article 113 Unless otherwise specified in these Measures, if government subsidy funds are involved, Shangcheng District, Xiacheng District, Jianggan District, Gongshu District, Xihu District, Hangzhou High-tech Development Zone (Binjiang), Hangzhou Qiantang New District and Hangzhou West Lake Scenic Area shall be borne by the municipal and district finance at a ratio of 1:1; Xiaoshan District, Yuhang District, Fuyang District, Lin ‘an District, Tonglu County, Chun ‘an County and jiande city shall be borne by each district and county (city) under the existing financial system. If the urban financial system is adjusted, the sharing ratio will be adjusted according to the new regulations.

Article 114 These Measures shall come into force as of January 1, 2021, and the municipal medical security administrative department shall take the lead in organizing the implementation. Before the implementation of municipal overall planning of medical insurance, Tonglu County, Chun ‘an County and jiande city and other three jurisdictions can implement the financing standards and treatment policies of basic medical insurance as stipulated in these Measures step by step according to the local economic and social development level and the actual operation of medical insurance funds. Unless otherwise stipulated by the state or province, such provisions shall prevail. Previously issued the Notice of Hangzhou Municipal People’s Government on Printing and Distributing the Measures for Basic Medical Security in Hangzhou (Hangzhou Zheng [2017] No.64), the Notice of the General Office of Hangzhou Municipal People’s Government on Printing and Distributing the Measures for Maternity Insurance in Hangzhou (Hangzhou Zhengban [2011] No.22) and the Notice of the General Office of Hangzhou Municipal People’s Government on Printing and Distributing the Detailed Rules for the Implementation of the Measures for Basic Medical Security in Hangzhou (Hangzhou Zhengban [2017] No.6)

　　　 Living organ transplantation is a modern medical method that has developed rapidly in recent decades. Through living organ transplantation, countless critically ill patients have been cured and reborn. However, at the same time, this door still needs continuous improvement of medical technology, and there are also many mysteries that are still difficult to explain clearly. And many ugly and even vicious criminal cases that followed.

　　　 In Europe, America, even Japan and South Korea, it is not uncommon to make a fuss about living organ transplantation and create a scary atmosphere. However, in mainland China, it is exclusive to tell cases related to living organ transplantation. A Beating Heart tells the story of a mysterious murder caused by a heart transplant operation.

　　　 Around the heart transplant surgery in the film, the director successfully threw out a concept — — Heart memory, which roughly means that patients undergoing heart transplantation are likely to accept or even completely inherit the memory of the heart donor. The whole film "Desperate Heartbeat" is basically around the knowledge point of "heart memory" to make a fuss, and launched a thrilling and suspenseful story.

　　　 Regarding the phenomenon of "heart memory", there have always been similar cases among many examples of heart transplant operations around the world, but due to the insufficient development of science and technology at present, a reasonable explanation has never been given to this phenomenon. Therefore, for this phenomenon, the general view of the medical community is not to deny its existence, but not to make redundant explanations.

　　　 In the film "Desperate Heartbeat", Lin Xilei, who underwent a heart transplant, felt as if she had become another woman because of her "heart memory" — — Jiangbei Yan. Tony Leung Ka Fai, who performed a heart transplant for her, seems to have something else to hide. All the characters in the film seem to have ulterior motives. Around the heart of Lin Xilei, a life-and-death struggle is staged in horror. What is the truth behind the scenes? Only in late June, after the film is released in major theaters all over the country, wait for the audience to go to the theaters in person and find out!

Original Zhu Xinpu Yun Dan Gongbu Zhu Xinpu Stroke Prevention Science Popularization

Sudden cardiac death (SCD) is an unpredictable natural death caused by heart, accounting for about 80% of sudden death. The main manifestations are acute onset, with more males than females. A variety of heart diseases can lead to sudden death, especially those with organic basic cardiovascular diseases or related risk factors. Patients may have a history of heart disease or heart disease in the past. At present, it is recognized that most of the deaths within one hour of onset are sudden cardiac death.

According to the China Cardiovascular Disease Report released in 2019, there are 544,000 cases of sudden cardiac death in China every year.

1. Coronary artery disease

It mainly includes coronary heart disease (coronary atherosclerotic heart disease), acute myocardial infarction, coronary thrombosis, embolism or spasm, coronary arteritis, congenital coronary artery dysplasia, etc., among which coronary heart disease is the most common.

As the most common cause of sudden death, coronary heart disease is seen in acute coronary syndrome (including acute myocardial infarction and unstable angina pectoris). According to the American Heart Association, 25% of patients with coronary heart disease take sudden cardiac death as the first clinical manifestation. According to the domestic literature, 80% of adult deaths from sudden cardiac death are related to acute coronary syndrome. These patients died of acute myocardial ischemia.

The etiological basis of coronary heart disease is atherosclerosis, which leads to the decrease of coronary blood flow and myocardial perfusion. Under the inducement, acute coronary spasm or microcirculation embolism can occur, causing acute myocardial ischemia, causing electrophysiological disorder, leading to malignant arrhythmia and even sudden cardiac death.

2.cardiomyopathy

Hypertrophic cardiomyopathy is the most common cause of sudden cardiac death in cardiomyopathy. Hypertrophic cardiomyopathy (HCM) is a complex hereditary cardiomyopathy characterized by thickening of left ventricular wall, which has various clinical and genetic manifestations. It is a common cause of sudden death in adolescents, with a high missed diagnosis rate and 50% family history.

The research shows that the risk of sudden cardiac death such as having a history of ventricular tachycardia attack, severe left ventricular wall hypertrophy (≥30mm), unexplained syncope, family history of sudden cardiac death and exercise-related hypotension is obviously increased. It is suggested that all patients with family history of sudden death should be screened by echocardiography.

3. valvular disease

Cardiac valvular disease is also one of the risk factors of sudden cardiac death, including mitral stenosis and/or insufficiency, aortic stenosis and/or insufficiency, infective endocarditis, mitral valve prolapse (MVP) or chordae tendineae rupture. For example, severe aortic stenosis can cause a serious decrease in blood flow into the aorta and cardiac output, leading to sudden cardiac death.

In China, the incidence of valvular heart disease is high, which is mainly caused by rheumatic diseases, trauma, degeneration, congenital malformation, inflammation and other reasons. The structural function of one or more valves is abnormal, resulting in stenosis and/or insufficiency of the valve orifice.

4. Structural heart disease

Structural heart disease is a general term for a large class of diseases caused by abnormal heart structure, which mainly includes: congenital heart structure abnormality, valve abnormality, coronary artery dysplasia, acquired valve disease and so on.

Congenital cardiovascular diseases mainly include atrial septal defect, ventricular septal defect, patent ductus arteriosus, coarctation of aorta, congenital aortic or pulmonary valve stenosis, tetralogy of Fallot and so on. Such diseases increase the risk of sudden cardiac death. In particular, patients with left-to-right shunt congenital heart disease who develop to Eisenmenger syndrome and complex congenital heart disease are more prone to sudden cardiac death.

Abnormal coronary artery is the main cause of sudden death in young people. Especially after strenuous exercise. The clinical manifestations are angina pectoris, arrhythmia, syncope and even sudden cardiac death after strenuous exercise. Therefore, for special people who have uncomfortable symptoms after exercise, athletes and so on, congenital coronary artery dysplasia should be screened out.

5. Aortic disease

Aortic disease is one of the important factors leading to sudden cardiac death, and its main pathogenesis is fatal ischemia of target organs caused by aortic rupture and involvement of important branches. Among them, Stanford A aortic dissection is the most dangerous, and the main causes of sudden cardiac death include: aortic rupture, pericardial tamponade, dissection involving coronary artery leading to large-scale myocardial infarction, and involvement of brachiocephalic artery leading to cerebral infarction.

6. Pulmonary embolism

Pulmonary thromboembolism is a common emergency in cardio-pulmonary vascular diseases, and its incidence and mortality are extremely high.

The embolus source of pulmonary embolism can be endogenous or exogenous, and the embolic site is mainly in the trunk or main branch of pulmonary artery. Clinically, pulmonary embolism thrombus mainly comes from venous system or right atrial appendage. When patients have pulmonary embolism, pulmonary circulation disorder can occur in a short time, and sudden cardiac death can occur in severe cases.

In daily life, sudden cardiac death caused by pulmonary embolism is most common in "economy class syndrome", that is, the lower limbs are in a state of braking for a long time, which leads to venous thrombosis. Once a large thrombus falls off, it will lead to acute pulmonary embolism, and then sudden cardiac death can occur.

In addition, a considerable number of patients’ thrombi come from the right atrial appendage, mainly due to atrial fibrillation, so for such patients, it is also necessary to be alert to the occurrence of sudden cardiac death caused by pulmonary embolism.

7. Abnormal cardiac electrophysiological activity

Abnormal primary ECG or abnormal ion channels can induce sudden cardiac death, such as sinoatrial node lesions and abnormal cardiac conduction system (Lenegre disease or Lev disease, WPW syndrome, Q-T interval extension syndrome). This is an important cause of sudden death of teenagers.

Once the cardiac electrophysiological abnormality occurs, it may induce cardiac pacing conduction disorder, eventually leading to complete atrioventricular block, and even fatal arrhythmia such as ventricular tachycardia and ventricular fibrillation may occur, which may lead to insufficient blood output from the heart to brain tissue and the whole body, resulting in shock and syncope. If cardiac arrest lasts for 5 minutes, it can cause irreversible brain tissue damage and death, which will eventually lead to sudden cardiac death.

Sometimes, viral infection and other diseases may also involve the cardiac electrical conduction system, which increases the risk of sudden death of patients.

8. Explosive myocarditis

Early mortality is extremely high, which is another important cause of sudden cardiac death in children and young adults. The early symptoms of myocarditis are very similar to the common cold, only "a little uncomfortable", which is difficult to attract attention.

9. Kawasaki disease

The etiology is not clear yet. At present, it is considered that some patients are immune-mediated systemic vasculitis triggered by various infectious pathogens (viruses, bacteria, etc.). Kawasaki disease mostly occurs in children, which is one of the main causes of sudden death of children. Having Kawasaki disease in childhood can also cause myocardial infarction in adults.

10. Others

Other causes of sudden cardiac death mainly include: acute pericardial tamponade, intracardiac thrombosis, electrolyte disorder, sleep apnea and gene correlation.

Original title: How much do you know about sudden cardiac death? 》

Read the original text

CCTV News:In Chongqing, with the optimization and adjustment of epidemic prevention and control policies, the number of emergency department patients in the First Affiliated Hospital of Chongqing Medical University surged, especially the number of emergency medical patients increased by 4-5 times, most of whom were infected by Covid-19. In the past two days, the reporter from the reception desk came to the emergency department of the hospital and recorded the work of medical staff.

As soon as the reporter arrived at the hospital, a 120 ambulance was ready to leave. The doctor Deng Ying told us that they were going to the nursing home to pick up a critically ill patient. When they came to the nursing home, Deng Ying and the nurse learned that the old man had not eaten for several days and had symptoms such as difficulty breathing.

After carrying the old man to the ambulance, the nurse on board quickly inserted oxygen into the old man and connected the monitoring equipment. Ten minutes later, the ambulance rushed back to the hospital from the nursing home, but there was no bed in the emergency room. What was even more worrying was that the family members could not be contacted.

Although the family members could not be contacted, the first aid could not wait. Several medical staff quickly added a bed for the elderly and made various emergency treatments.

With the cooperation of several medical staff, Deng Ying finished the examination for the elderly. According to the examination results, they gave the elderly corresponding treatment and plan. Soon, the problems such as poor breathing of the elderly were alleviated. Deng Ying said that recently, due to the shortage of emergency personnel, she was transferred from obstetrics and gynecology to support. At present, there are 22 doctors in the emergency department, many of whom are transferred from other departments like Deng Ying. Most of them have been infected with Covid-19. Faced with the emergency volume of more than 400 people at the peak, they are a little tired, but they still try their best to treat every patient.

At the moment, the medical staff in the emergency department are rescuing a 19-year-old boy. Because of renal insufficiency and other diseases, the boy developed respiratory failure after being infected with Covid-19, and he is in urgent need of ventilator support.

After the coordination of the dean, a bed was finally found in the respiratory intensive care unit, but the department’s non-invasive ventilator had been used up and had to be transferred from the geriatrics department. The patient was successfully transferred to the respiratory intensive care unit. Five hours later, the reporter came to the intensive care unit again and found that all the indicators of the patient’s body tended to be stable.

According to the hospital, at present, the beds in various departments, especially the emergency department, have been overloaded. How to ensure that patients can be treated in time and that critically ill patients can live in the intensive care unit in the later stage?

Zhou Fachun, Director of Department of Critical Care Medicine, First Affiliated Hospital of Chongqing Medical University:Patients with relatively stable condition can be transferred to other specialized wards at the first time, so as to ensure that the utilization rate of ICU beds can really serve the critical patients in need.

For non-critical patients, neurology, cardiovascular medicine and other departments have also vacated many beds.

In the emergency department, doctors and nurses are still busy, and 2023 has quietly arrived.

It’s winter.
High incidence of respiratory infectious diseases
But can you tell what kind of infection it is?
Collect it! This article answers your questions!

　　1. What are the clinical manifestations of mycoplasma pneumoniae infection?
　　Mycoplasma pneumoniae is mainly infected by respiratory tract, which can cause pneumonia, often accompanied by pharyngitis and bronchitis.
　　The onset of mycoplasma pneumoniae infection is generally slow, and patients often have chills, fever and dry cough, which may be accompanied by symptoms such as stuffy nose, fatigue and headache. Mycoplasma pneumoniae infection has certain self-limitation. In recent years, the proportion of refractory mycoplasma pneumonia and severe mycoplasma pneumonia has increased among school-age children.

　　2. What are the clinical manifestations of respiratory syncytial virus infection?
　　In the early stage of respiratory syncytial virus infection, the main symptoms are upper respiratory tract infection, such as nasal congestion, runny nose, cough and hoarseness, and most of the symptoms will disappear by themselves in 1-2 weeks.
　　A few cases can develop into lower respiratory tract infections such as bronchiolitis or pneumonia, which are more common in infants under 2 years old.

　　3. What are the clinical manifestations of adenovirus infection?
　　Adenovirus infection has various clinical manifestations, which can cause common cold, bronchitis and pneumonia, diarrhea and gastroenteritis, conjunctivitis, cystitis and some nervous system inflammation.
　　People with chronic respiratory diseases, heart diseases or low immune function may have serious clinical symptoms after being infected with adenovirus.

　　4. What are the clinical manifestations of rhinovirus infection?
　　Rhinovirus infection can cause symptoms of upper respiratory tract infection such as nasal congestion, runny nose, sneezing, sore throat, fever or cough, and can also lead to wheezing and asthma aggravation in children.
　　Infants or children with basic diseases infected with rhinovirus may cause lower respiratory tract infections such as bronchiolitis and pneumonia. The infection of rhinovirus in the elderly can increase the risk of chronic obstructive pulmonary disease, and the infection of hospitalized patients can lead to prolonged hospitalization.

　　5. What are the clinical manifestations of human metapneumovirus infection?
　　The incubation period of human metapneumovirus infection is 3~5 days, which often causes symptoms of upper respiratory tract infection, such as fever, cough, nasal congestion, runny nose and hoarseness, which are slightly self-limited, and the symptoms gradually ease in about 1 week.
　　Children, the elderly and immunocompromised people may have bronchiolitis, pneumonia or acute respiratory distress syndrome after infection.

　　6. What is the difference between the clinical manifestations of influenza, mycoplasma pneumoniae infection and common cold in children?
　　The clinical manifestations of influenza, mycoplasma pneumoniae infection and common cold in children are different, and the main differences are shown in the table below.
　　The clinical manifestations of respiratory tract infectious diseases are usually not specific, and there are individual differences among patients, so they can not be differentiated only by symptoms and signs, and usually need laboratory tests to diagnose.

　　

　　7. What are the commonly used therapeutic drugs for respiratory tract infection pathogens in adults?
　　Recently, viruses and mycoplasma are the main pathogens causing respiratory tract infections. At present, there are mabaloxavir, oseltamivir and palamivir for influenza virus, nematevir/ritonavir, sennotvir/ritonavir, Monola vir and deuterium hydrobromide for Covid-19, and macrolides (such as azithromycin), fluoroquinolones (such as moxifloxacin and levofloxacin) and tetracyclines (such as doxycycline and levofloxacin) for mycoplasma.
　　Some infections caused by viruses or mycoplasma will be secondary to bacterial infections. At this time, it is necessary to use antibiotics reasonably under the guidance of doctors to avoid drug resistance. Commonly used antibiotics include penicillins (such as amoxicillin/clavulanic acid), cephalosporins (such as cefaclor, cefuroxime and cefdinir), fluoroquinolones (such as moxifloxacin and levofloxacin) and macrolides (such as azithromycin). It is worth noting that the above drugs are all prescription drugs and need to be used under the guidance of a doctor.
　　If you are self-tested for influenza virus antigen or Covid-19 antigen, and have serious high-risk factors such as age over 65, body mass index (BMI) over 40kg/m, basic diseases (such as chronic obstructive pulmonary disease, tumor, immune system diseases, etc.) or pregnancy, it is suggested to take orally anti-influenza drugs oseltamivir or mabaloxavir or oral anti-Covid-19 drugs within 48 hours of onset. If respiratory symptoms get worse, you should seek medical advice promptly.

　　8. What drugs are commonly used by children to treat pathogens of respiratory infections?
　　Children infected with influenza virus can take neuraminidase inhibitors such as oseltamivir, and children over 5 years old can also choose RNA polymerase inhibitors such as mabaloxavir.
　　After children are infected with mycoplasma pneumoniae, the first choice is macrolide drugs, such as azithromycin, clarithromycin and roxithromycin. The alternative drugs are new tetracyclines (such as doxycycline and minocycline) and quinolones. Tetracyclines are only used for children over 8 years old because they may cause yellowing of teeth and hypoplasia of enamel.
　　Children and adolescents under the age of 18 who use quinolones need doctors to strictly evaluate the indications and pay attention to the side effects of the drugs.

　　9. What are the precautions in diet during respiratory infection?
　　During the period of respiratory infection, on the one hand, due to fever, cough, fatigue and other conditions, the patient’s appetite decreased compared with usual; On the other hand, respiratory tract infection leads to the increase of energy consumption and the increase of energy demand.
　　Therefore, it is particularly important to supplement nutrition in a reasonable and balanced way and ensure the supply of energy. People with decreased digestive function can eat less and eat more to ensure adequate energy intake.
　　(1) Recommended food:
　　① Highly nutritious and digestible foods: such as lean meat, chicken, fish, tofu, etc. These foods are rich in protein, which helps to repair body tissues.
　　2 foods rich in vitamins: fresh fruits and vegetables, such as oranges, kiwis, carrots and spinach, are rich in vitamin C and other antioxidants, which helps to enhance immunity.
　　③ Whole grains and foods rich in cellulose, such as oats, whole wheat bread and brown rice, provide necessary energy and cellulose.
　　4 Adequate water: Ensure adequate water intake, such as drinking water, juice or soup, which helps to keep the body water balance and relieve sore throat.
　　(2) Foods that are not recommended or need to be controlled:
　　Oily and spicy foods, high-sugar foods, caffeinated drinks, etc.

The business review of the Board of Directors of Tuojing Technology in 2022 is as follows:

　　I. Description of the industry and main business of the company during the reporting period.

(a) the company’s industry

1. Industry and determination basis

The company is mainly engaged in R&D, production, sales and technical services of high-end semiconductor special equipment. According to the Guidelines for Industry Classification of Listed Companies (revised in 2012) issued by CSRC, the company belongs to the special equipment manufacturing industry (industry code: C35). According to the National Economic Industry Classification (GB/T4754-2017), the company belongs to the special equipment manufacturing of semiconductor devices under the special equipment manufacturing industry (industry code: C3562). According to the Classification of Strategic Emerging Industries (2018) issued by the National Bureau of Statistics, the company belongs to the integrated circuit manufacturing industry under the new generation of information technology industry.

2. Semiconductor equipment industry

The development level of semiconductor industry is closely related to the national science and technology level, and its development has become the vane of economic and social development in all countries around the world, and it is an important symbol to measure the modernization degree and scientific and technological strength of a country. As the technical leader of the semiconductor industry chain, semiconductor equipment is the foundation of the development of the semiconductor industry and the key to technological progress, and its self-control is particularly important. With the iterative upgrading of semiconductor technology, semiconductor components are gradually developing towards precision and miniaturization, which constantly challenges the manufacturing technology and makes the important position of semiconductor equipment increasingly prominent.

In recent years, driven by the rapid downstream development, the semiconductor equipment industry has maintained rapid growth. According to SEMI statistics, the global sales of semiconductor manufacturing equipment in 2021 was about USD 102.6 billion, up by 44% year-on-year. In 2021, the sales scale of semiconductor equipment in Chinese mainland reached USD 29.62 billion, up by 58% year-on-year. Chinese mainland was the largest market of semiconductor equipment in the world in 2020 and 2021. In the first quarter of 2022, the global shipment amount of semiconductor equipment reached US$ 24.7 billion, up 5% year-on-year. In the first quarter of 2022, the shipment amount of semiconductor equipment in Chinese mainland ranked first, up 27% year-on-year.

At present, the global semiconductor equipment market is mainly dominated by foreign manufacturers. With China’s continuous policy support and increased investment in the semiconductor industry, domestic semiconductor equipment has achieved a qualitative leap from scratch and from weak to strong, which has continuously improved the ecology and manufacturing system of China’s semiconductor industry. However, China’s semiconductor equipment market is still heavily dependent on imports. Therefore, the domestic semiconductor equipment manufacturers who can achieve import substitution have a large market space and have a huge growth opportunity.

3. Development of the film deposition equipment industry where the company is located.

(1) Market scale of thin film deposition equipment

According to the data of SEMI and Beijing Oulixin, the global market scale of thin film deposition equipment will reach 21 billion US dollars in 2021. According to the proportion of domestic semiconductor equipment market accounting for 28.87% of the global market in 2021, the market scale of thin film deposition equipment in Chinese mainland will be about 6 billion US dollars in 2021, which is about 33% higher than the estimated 4.5 billion US dollars in 2020. In 2022, the global market scale of thin film deposition equipment will continue to grow, which is expected to reach $25 billion, and the Chinese mainland market will also maintain the growth trend, bringing broad market space for domestic thin film equipment manufacturers.

According to SEMI statistics, in the equipment investment of newly-built fabs, the investment in equipment related to wafer manufacturing accounts for about 80% of the total equipment investment. As one of the three major equipment in wafer manufacturing, the investment scale of thin film deposition equipment accounts for 25% of the total investment in wafer manufacturing equipment.

Proportion of investment in semiconductor equipment

(2) Market situation of thin film deposition equipment segments focused by the company.

Thin film deposition equipment mainly includes chemical vapor deposition (CVD) equipment and physical vapor deposition (PVD) equipment. The company mainly focuses on plasma enhanced chemical vapor deposition (PECVD) equipment, sub-atmospheric chemical vapor deposition (SACVD) equipment and atomic layer deposition (ALD) equipment in the field of CVD equipment subdivision. Different kinds of thin film deposition equipment are suitable for different requirements of different process nodes on film quality, thickness and pore groove filling ability.

According to the data of SEMI and Beijing Oulixin, in 2021, PECVD is the highest equipment type among all kinds of thin film deposition equipment in the world, accounting for 33% of the total thin film deposition equipment market, ALD equipment accounts for about 11%, and SACVD belongs to other thin film deposition equipment categories, accounting for less than 6%.

Proportion of all kinds of thin film deposition equipment

(3) Development trend of thin film deposition equipment

① The market demand for thin film deposition equipment is growing steadily.

With the improvement of the overall prosperity of the semiconductor industry, the global semiconductor equipment market shows a rapid growth trend, which drives the market demand for thin film deposition equipment to increase. Maximize Market Research predicts that the global market size of semiconductor thin film deposition equipment will reach 34 billion US dollars in 2025, with a compound annual growth rate of 13.3% from 2020 to 2025. Among them, the market scale of ALD equipment will grow rapidly. According to the market research organization Acumen research and condulting, with the increase in the number of advanced semiconductor manufacturing lines, the global ALD equipment market will reach about 3.2 billion US dollars in 2026.

In recent years, driven by the strong market demand for semiconductor products, the global fabs have expanded their production capacity and gradually moved to Chinese mainland. Chinese mainland has become the new production center of global fabs. SEMI data shows that in 2021-2022, there were 29 new fabs in the world, including 8 in Chinese mainland, accounting for 27.59%. The expansion and construction of Chinese mainland Wafer Factory has accelerated the development and layout of domestic semiconductor industry, providing a huge market space for the development of domestic semiconductor equipment.

According to the statistics of Jiwei Consulting, Chinese mainland is expected to add 25 12-inch wafer factories in the next five years (2022 -2026), with a total planned monthly production capacity of over 1.6 million wafers. By the end of 2026, the total monthly production capacity of Chinese mainland 12-inch wafer fab will exceed 2.763 million wafers. The upsurge of local fabs in China will lead the demand growth of semiconductor thin film deposition equipment in China.

(2) chip technology progress and complicated structure improve the demand for thin film equipment.

Thin film deposition refers to the deposition of a layer of thin film material to be processed on the silicon wafer substrate. The deposited thin film material can be nonmetal such as silicon dioxide, silicon nitride, polysilicon and metal such as copper. Thin film deposition equipment is mainly responsible for the deposition of dielectric layer and metal layer in each step. PECVD, ALD and SACVD products focused by the company are mainly used to deposit dielectric thin film materials, which are widely used in logic chips, 3D NAND FLASH memory chips and DRAM memory chips.

Application of dielectric thin film in logic chip

Application of Dielectric Thin Film in 3D NAND FLASH Memory Chip

Application of dielectric film in DRAM memory chip

The development of thin film equipment supports the development of integrated circuit manufacturing technology to smaller processes. With the iterative upgrade of integrated circuit chip technology, the wafer manufacturing process is becoming more and more precise, the complexity of chip structure is increasing, the required thin film deposition processes and thin film types are increasing, and the requirements for thin film performance are also increasing. This trend puts forward higher technical requirements for thin film deposition equipment, and the market is increasingly dependent on high-performance thin film equipment.

In 90nm CMOS chip technology, about 40 thin film deposition processes are needed. In the production line of 3nm FinFET process, more than 100 thin film deposition processes are needed, and the number of thin film materials involved has increased from 6 to nearly 20, and the requirements for thin film particles have also increased from micron level to nanometer level, thus driving the wafer factory to increase the demand for thin film deposition equipment.

Comparison of thin film deposition processes at different process nodes

In the field of FLASH memory chips, with the development of mainstream manufacturing technology from 2D NAND to 3D NAND structure, the complexity of the structure leads to the increasing demand for thin film deposition equipment. With the increasing number of stacked layers of 3D NAND FLASH chips, from 32/64 layers to 128/196 layers and more advanced nodes, the demand for thin film deposition equipment will continue.

Although the global semiconductor equipment market has a strong periodicity, Chinese mainland’s semiconductor industry is facing unprecedented development opportunities, with national strategic focus, huge market support, benign interaction of industrial chains, increasing industrial capital, increasing number of fabs invested by mainland and international capital, and more advanced manufacturing processes. China’s thin film deposition equipment industry will maintain high growth, and the importance of China market will be further enhanced in the future.

(2) Description of the main business.

1. Overview of the company’s main business

The company is mainly engaged in research and development, production, sales and technical services of high-end semiconductor special equipment. The company’s main products include plasma enhanced chemical vapor deposition (PECVD) equipment, atomic layer deposition (ALD) equipment and sub-atmospheric chemical vapor deposition (SACVD) equipment, which have been widely used in the production line of 14nm and above process integrated circuits in domestic fabs, breaking the monopoly of international manufacturers on the domestic market in the field of high-end semiconductor thin film deposition equipment and competing directly with international oligarchs. At present, the company is the only manufacturer of integrated circuit PECVD equipment and SACVD equipment for industrial application in China, and also the leading manufacturer of integrated circuit ALD equipment in China.

2. The company’s main products

During the reporting period, the company continued to expand the application fields of PECVD, ALD and SACVD products, continuously enriched and improved the functions of mass-produced products, maintained the core competitiveness of products, further enhanced the market share of existing products, and obtained repeated orders from existing customers and new customers in the fields of logic chips and memory chips. The scale of mass production and application of the company’s products in the wafer manufacturing production line continues to expand. By the end of the reporting period, the cumulative number of products produced by the company’s equipment in the client production line has increased from more than 46 million as of December 2021 to more than 71 million. During the reporting period, the company’s equipment performed well in the production and operation stability of the client production line, and the average Uptime of the machine was over 90% (the industry standard is usually over 85%).

On the basis of existing products, the company has actively deployed new product research and development around the subdivision of CVD equipment, and continuously enriched the company’s product categories. At present, it has developed new products such as TS-300 (polygonal high-yield platform), thermal-atomic layer deposition (Thermal-ALD) based on high-yield platform, high-density plasma enhanced chemical vapor deposition (HDPCVD) equipment and ultraviolet curing (UV Cure) equipment.

The company’s existing PECVD, ALD and SACVD products are as follows:

①PECVD series products

PECVD equipment is one of the core equipment in chip manufacturing. Due to the action of plasma, high-density and high-performance thin films can be formed at relatively low reaction temperature, and the existing thin films and the formed underlying circuits are not damaged, thus achieving faster film deposition speed. It is the most widely used equipment type in the film deposition process of chip manufacturing.

The details of PECVD series products are as follows:

②ALD series products

ALD equipment can achieve excellent step coverage and accurate film thickness control with high aspect ratio and extremely narrow trench opening, and realize the precision control of key dimensions in chip manufacturing process. ALD is one of the essential core equipment in the manufacturing of advanced logic chips, DRAM and 3D NAND with complex structure and accurate film thickness requirements.

The company’s ALD series products are as follows:

③SACVD series products

SACVD equipment is mainly used in trench filling process and is one of the important equipment for integrated circuit manufacturing. In the integrated circuit structure, the depth-to-width ratio of trench holes is increasing, and the SACVD reaction chamber environment has a unique high temperature (400-550℃) and high pressure (30-600Torr) environment, which has a rapid and superior Gap fill ability.

The company’s SACVD series products are as follows:

Note: With the continuous enrichment of the company’s product categories, the company continues to improve the product model naming rules. During the reporting period, the company’s product model name was adjusted by implementing the internal decision-making procedures of the company, and the product model was renamed according to the type of equipment platform and the type of reaction chamber.

3. Main business models

(1) Profit model

The company is mainly engaged in research and development, production, sales and technical services of high-end semiconductor special equipment. The company realizes revenue and profit by selling film deposition equipment to downstream customers and providing spare parts and technical services. During the reporting period, the company’s main business income came from the sales of semiconductor equipment, and other business income mainly came from the sales of spare parts related to equipment.

(2) R&D mode

The company mainly adopts the mode of independent research and development. The company has established an international and professional research and development technical team for semiconductor thin film deposition equipment. The company’s R&D technical team has a reasonable structure, clear division of labor, profound professional knowledge reserves and rich experience in production line verification, which is the cornerstone of the company’s independent R&D capability. Guided by customer demand, technical trends of semiconductor special equipment and national major scientific and technological special goals, the company develops and designs new products and processes, manufactures R&D machines, and debugs performance parameters. After passing the company’s test, it is sent to the customer’s actual production environment for industrialization verification, and the products are formally finalized after verification. In addition, the company will continue to enrich and improve the functions of mass-produced products according to the different process application needs of customers.

(3) Purchasing mode

Company procurement is mainly divided into standard parts procurement and non-standard parts procurement. For the procurement of standard parts, the company directly purchases from market suppliers. Non-standard parts are mainly parts designed by the company according to specific technical requirements in R&D and production. For non-standard parts procurement, the company mainly provides design drawings to suppliers and defines parameter requirements, and suppliers purchase raw materials for processing and customization; For specific parts, the company provides drawings and parameters, and supplies raw materials to suppliers, entrusting suppliers to complete customized processing.

(4) production mode

The company’s products are mainly customized and manufactured according to customers’ differentiated needs and purchasing intentions. The company mainly adopts the production mode of combining inventory production with order production. Inventory-based production means that the company starts production before obtaining the formal order, including the production activities started according to the Demo order or the clear customer purchase intention, which is applicable to the company’s Demo machines and some sales machines. Order-based production refers to the production after the company signs a formal order with the customer, which is suitable for most of the company’s sales machines.

(5) Sales and service mode

During the reporting period, the company’s sales model was direct sales, and customers’ orders were obtained through business negotiations with potential customers and bidding. After years of efforts, the company has formed a relatively stable cooperative relationship with domestic semiconductor industry enterprises.

The company’s sales process generally includes market research and promotion, obtaining customer demand and internal discussion, product quotation, bidding operation and management (if applicable), sales negotiation, contract review, signing and execution of sales orders (or Demo orders), product installation and debugging, contract payment, customer acceptance and after-sales service. After the company’s equipment is shipped to the customer’s designated place, it needs to be installed and debugged on the customer’s production line. Usually, after the customer completes the relevant tests, the equipment is accepted, and the company confirms the income after the customer’s acceptance is completed.

During the reporting period, the company’s main business model has not changed significantly.

Second, the core technology and research and development progress

1. Core technologies and their advanced features and changes during the reporting period.

Since its establishment, the company has been focusing on the research and development of semiconductor thin film deposition equipment, forming a series of core technologies with independent intellectual property rights, and reaching the international advanced level. The company’s core technology is widely used in its main business products, which solves the key problems in semiconductor manufacturing, such as uniformity and consistency of nano-scale thin films, small number of particles on the film surface, rapid film formation and stable and high-speed equipment production capacity. While ensuring the realization of film process performance, it improves the production capacity of customer production lines and reduces the production cost of customer production lines. The company’s core technology and its advanced features are as follows:

During the reporting period, the company’s core technology has not changed significantly.

Awards of national science and technology awards

Identification of "individual champions" of national-level "little giant" enterprises and manufacturing industries

2. R&D achievements obtained during the reporting period

The company has always focused on the research and development of semiconductor thin film deposition equipment. During the reporting period, the company was approved to undertake one major national special project. By the end of the reporting period, the company had undertaken seven major national special projects/projects.

The company has a number of independent intellectual property rights and core technologies. By the end of the reporting period, the company had applied for 502 invention patents, 101 utility model patents, 1 design patent and 21 PCT21 patents. A total of 107 invention patents, 79 utility model patents and 1 design patent were obtained.

On April 15th, 2022, China National Intellectual Property Administration announced the pre-winners of the 23rd China Patent Award, and the company’s patent "Load Chamber and Multi-chamber Processing System Using the Load Chamber" was shortlisted for the China Patent Excellence Award.

List of intellectual property rights acquired during the reporting period

3. R&D investment table

Reasons for significant changes in total R&D investment compared with the previous year

During the reporting period, the company continuously enriched the product categories, expanded the application fields of technology, and continuously increased the investment in R&D. The company invested 118 million yuan in R&D in this period, up 45.66% year-on-year, mainly due to the direct investment in R&D and the increase in the salary of R&D personnel.

Reasons for the great change in the capitalization proportion of R&D investment and its rationality

4. Research projects

5. R&D personnel

6. Other explanations

Second, the discussion and analysis of the business situation

During the reporting period, the company has been deeply involved in the field of high-end semiconductor equipment, focusing on the research and development and industrial application of thin film deposition equipment. Focusing on the national special strategic layout, facing the development of domestic integrated circuit chip manufacturing technology and market demand, the company gives full play to its advantages in R&D team, technical reserve, customer resources and after-sales service, seizes the market opportunity of rapid development of domestic semiconductor industry, persists in driving business development with technology and product innovation, continuously maintains the R&D and investment of new products, new processes and new technologies, enhances the market competitiveness of products, and at the same time, continuously strengthens the operation and management of the company to promote its sustained, steady and rapid development.

1. Main business conditions

During the reporting period, the company’s products continued to maintain their competitive advantage, and benefited from the capacity expansion of downstream fabs and the strong support of national policies for domestic equipment. The company’s product sales increased significantly year-on-year, achieving an operating income of 523,216,900 yuan, an increase of 364.87% over the same period of last year, and the operating income increased significantly; The net profit attributable to shareholders of listed companies was 108,122,700 yuan, and the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 49,150,300 yuan, turning losses into profits compared with the same period of last year, and the profitability continued to increase.

During the reporting period, the company realized the main business income of 516,667,400 yuan, an increase of 392.56% over the same period of last year. The analysis of the company’s main business by product category is as follows:

During the reporting period, the company’s main business income mainly came from the sales income of PECVD equipment, ALD equipment and SACVD equipment, among which PECVD equipment was the most important source of the company’s main business income, while ALD equipment and SACVD equipment realized income compared with the same period.

2. The company’s product development and industrialization progress

During the reporting period, the company continued to maintain a high level of R&D investment, gradually improved the technological innovation capability of existing products, maintained the core competitiveness of products, continuously enriched the types of equipment, and broadened the coverage of film technology products, and made breakthroughs and progress in product industrialization and new product research and development.

(1) Progress of industrialized application of existing products

①PECVD series products

During the reporting period, the company’s PECVD(PF-300T (two-station)) equipment continued to maintain its competitive advantage, the order volume increased steadily, and the market share continued to increase, which has been accepted by existing and new customers. By the end of the reporting period, the company’s PECVD(PF-300T) equipment has been widely used in domestic wafer manufacturing production lines, including 28nm and above logic chips, 3DNANDFLASH, DRAM memory chip manufacturing and other fields.

PECVD(NF-300H (six-station)) equipment introduced by the company has achieved the first industrial application in the field of DRAM memory chip manufacturing, and can deposit ThickTEOS dielectric thin films. The equipment can process up to 18 wafers at a time, with high yield and good performance index, which broadens the application coverage of the company’s process.

②ALD series products

During the reporting period, the verification of the company’s PE-ALD series products in the manufacturing fields of logic chips, 3DNANDFLASH and DRAM memory chips progressed smoothly, and the ALD reaction chamber passed the acceptance of existing customers. At the same time, the company is oriented by customer demand and actively deploys the application and expansion of PE-ALD advanced film technology. By the end of the reporting period, the company’s PE-ALD series products have been industrialized in the field of logic chips, which can deposit SiO2 _ 2 dielectric materials with high temperature, low temperature and high quality.

By the end of the reporting period, the company’s Thermal-ALD(PF-300T (two-station)) equipment has completed product development and obtained customer orders, and has been continuously optimized and improved according to customer index requirements.

③SACVD series products

During the reporting period, the company’s SACVD products continued to expand their application fields, and BPSG and SATEOS thin film processes obtained customer acceptance in the field of 40/28nm logic chip manufacturing. By the end of the reporting period, SACVD products of the company have been widely used in the field of logic chip manufacturing of 12-inch 40/28nm and 8-inch 90nm or above, and have obtained orders from existing and new customers.

(2) Progress of new products

During the reporting period, the company continuously enriched the types of equipment in the field of CVD subdivision, expanded the product coverage, and developed TS-300 (polygonal high-yield platform), Thermal-ALD based on high-yield platform, and high-density plasma enhancement.

Learn new products such as vapor deposition (HDPCVD) equipment and ultraviolet curing treatment (UVCure) equipment, and make breakthroughs and progress. The details are as follows:

①TS-300 (Polygon High-yield Platform)

Based on the existing platform, the company developed and designed the design of hexagonal transmission platform, which can carry up to five reaction chambers (10 reaction stations) at the same time, improve the productivity of thin film deposition equipment, and at the same time, integrate and combine various processes to realize continuous multi-step deposition in vacuum environment. The company’s polygonal high-capacity platform can be equipped with PECVD reaction chamber, ALD reaction chamber and HDPCVD reaction chamber, and has obtained orders from existing and new customers.

②ALD series products

Based on Thermal-ALD(PF-300T (Two-station)) equipment, the company developed Thermal-ALD(TS-300 (Polygonal High-yield Platform)) equipment, which can improve the production capacity, at the same time, integrate and combine various thin film processes, and can deposit various metal compound thin film materials such as Al2O3 and AlN, and has obtained customer orders.

③HDPCVD series products

High-density plasma enhanced chemical vapor deposition (HDPCVD) equipment can deposit and sputter thin films at the same time, so as to fill trenches with the aspect ratio less than 5:1. The films deposited by HDPCVD have higher density and lower impurity content, which is mainly suitable for the field of 130-55nm process logic chip manufacturing. The company has developed HDPCVD(PF-300T (single station)) equipment and HDPCVD(TS-300 (polygonal high-yield platform)) equipment, which can deposit thin films of dielectric materials such as SiO2 _ 2, FSG and PSG. HDPCVD series (PF-300T (single station)) equipment has been shipped to the client for industrial verification. Both of the above two equipments have obtained customer orders.

④UVCure equipment

UVCure equipment is mainly used for ultraviolet curing of thin films, which can effectively improve the efficiency and thermal budget of post-treatment process of thin films, and improve key performance indexes such as stress, granularity and hardness of thin films. The company’s UVCure equipment has been designed and developed, which can be used in complete sets with PECVD equipment to carry out UV curing treatment for PECVDLokII, HTN and other thin film deposition. It has been shipped to the client for industrial verification and obtained customer orders.

3. Supply chain security

The company continuously optimized the supply chain management system and established a multi-dimensional coordination mechanism covering production and inventory management, procurement management and logistics management. The company has always attached great importance to the cultivation of suppliers, continuously improved the supplier support and performance appraisal mechanism, and promoted the continuous improvement of supplier product quality and product performance. Under the background of global supply chain tension and epidemic situation, the company strengthened the depth and scope of cooperation with suppliers, constantly adjusted and optimized the supply chain structure by planning in advance and sharing demand forecast, and adopted a global and multi-source supply strategy. At the same time, according to customer demand and R&D demand, the volume and progress of parts procurement are reasonably planned to ensure the timely and stable supply of key parts. During the reporting period, the company’s upstream supply chain remained generally stable, effectively ensuring the smooth progress of production.

4. Market sales

During the reporting period, the company continued to focus on the thin film deposition market in Chinese mainland, and seized the market opportunities brought by the expansion of domestic downstream wafer manufacturing plants. With the core competitive advantages of the company’s products, the market share and customer recognition continued to increase: (1) the company’s three series of products and new products, PECVD, ALD and SACVD, obtained existing and new customer orders; (2) The verification of the company’s products in the customer’s production line progressed smoothly and achieved good results. The scale of mass production and application in the wafer manufacturing production line continued to expand, and the sales volume of products increased significantly year-on-year; (3) The company continues to maintain in-depth and stable cooperation with downstream customers and continue to provide customized high-performance products, laying a solid foundation for the company’s future business growth.

5. Talent team building

During the reporting period, the company continued to strengthen the construction of talent echelon and expand the scale of personnel according to the needs of business development. In terms of talent introduction, actively attract experienced management and technical talents in the industry, and select outstanding graduates from domestic universities. In terms of personnel training, the company continuously optimizes the training system, gives full play to the performance appraisal and incentive mechanism, and enhances the sense of honor and cohesion of employees; Continue to strengthen close cooperation with universities and implement targeted recruitment linked with factories and schools; Establish a joint training mechanism with domestic universities to train reserve talents directionally, which provides strong support for the construction of the company’s talent team.

6. Operation management

During the reporting period, the company continuously improved the product manufacturing level, optimized the material operation management, and effectively improved the timely rate and qualified rate of assembly and manufacturing. The company continuously strengthens the product quality management system, and maintains a high level of after-sales technical support services to enhance customer satisfaction. The company has an EHS (Environment, Health and Safety) compliance management department to supervise the company’s production and operation to ensure the compliance and safety of the company’s production. The company actively arranges information system technical protection and security management to ensure the company’s network security and data security.

7. The company’s initial public offering and progress in the construction of fundraising projects.

During the reporting period, the company completed the initial public offering and listed on the science and technology innovation board of Shanghai Stock Exchange. This initial public offering issued 31,619,800 shares of RMB common stock (A shares) to the public, with the par value of RMB 1 yuan per share, and the issue price was RMB 71.88 per share. The total amount of funds raised was RMB 2,272,831,200. After deducting the issuance expenses of RMB 145,234,000, The success of the company’s initial public offering provides a strong financial guarantee for the company to expand its production scale and develop new technologies and products.

The Company’s fundraising project "High-end Semiconductor Equipment Expansion Project" is the expansion project of "Semiconductor Film Equipment Industrialization Base (Phase I) Project", and the second phase of clean workshop construction, supporting facilities and production automation management system construction are carried out on the basis of the company’s original semiconductor film equipment R&D and production base. During the reporting period, the second-phase clean workshop was basically completed and put into production, and the layout of production automation management system was carried out at the same time.

The third fundraising project, ALD Equipment R&D and Industrialization Project, relies on the advantages of integrated circuit industrial cluster in the new area and talents in Shanghai, and strives to recruit first-class R&D teams to conquer high-end chip manufacturing thin film deposition equipment. During the reporting period, the company’s R&D and industrialization base construction is progressing smoothly, and ALD products have been developed.

8. Foreign investment

During the reporting period, the Company made the following investments:

(1) Establish a wholly-owned subsidiary in the United States.

During the reporting period, the company set up a wholly-owned subsidiary, Tuojing USA. The establishment of this company is conducive to the company to strengthen supply chain cooperation and investigate the international market. As of the end of the reporting period, Tuojing USA has not actually operated.

(2) Capital increase to Tuojing Shanghai

On June 17, 2022, the company held the 11th meeting of the first board of directors, deliberated and passed the Proposal on Using the raised funds to increase capital to wholly-owned subsidiaries to implement fundraising projects, and agreed that the company would use the raised funds to increase capital to Tuojing Shanghai by 270 million yuan to implement the fundraising project "ALD Equipment R&D and Industrialization Project". After this capital increase, the company will accelerate the research and development and industrialization of ALD equipment, improve the layout of the company’s product line and improve the market competitiveness of the company’s products. On July 20, 2022, the company has paid the capital increase to Tuojing Shanghai. On August 9, 2022, Tuojing Shanghai completed the registration of industrial and commercial changes.

(3) Capital increase to Hengyunchang and equity participation in Hengyunchang

On June 17th, 2022, the company held the 11th meeting of the first board of directors, deliberated and passed the Proposal on Foreign Investment and Participation in Shenzhen Hengyunchang Vacuum Technology Co., Ltd., and agreed that the company would increase its capital to Hengyunchang by RMB 20 million with its own funds, accounting for 35,088% of the total share capital of Hengyunchang after the capital increase. Hengyunchang is mainly engaged in R&D, production and sales of RF power supply for semiconductor equipment, photovoltaic and industrial equipment, and has supplied RF power supply, RF matcher and other products for the company. This capital increase is conducive to the company to improve its industrial layout, which is consistent with the company’s strategic layout, has a synergistic effect with its main business, and can enhance the stability of the company’s upstream supply chain. On July 14th, 2022, the company has paid the capital increase to Hengyunchang. On August 8, 2022, Hengyunchang completed the registration of industrial and commercial changes.

9. Corporate governance

During the reporting period, the Company held a general meeting of shareholders, five meetings of the Board of Directors, one meeting of the Audit Committee of the Board of Directors, one meeting of the Remuneration and Assessment Committee of the Board of Directors and two meetings of the Board of Supervisors.

As a listed company, the company has continuously improved its governance structure in strict accordance with the requirements of the Company Law, the Securities Law, the science and technology innovation board Stock Listing Rules of Shanghai Stock Exchange and the Articles of Association of Tuojing Technology Co., Ltd., so as to improve the scientificity, rationality, compliance and effectiveness of management decisions, improve the level of corporate governance and standardized operation, and lay a good foundation for the realization of the company’s business objectives.

10. Company information disclosure and prevention of insider trading.

The company attaches great importance to the standardized operation of listed companies, information disclosure management and investor relations management. According to the relevant laws, regulations and departmental rules, the company has formulated internal systems for regulating the operation of shareholders’ meeting, board of directors, board of supervisors, information disclosure and investor management, and strictly abided by them. The company earnestly fulfills its obligation of information disclosure to ensure the timeliness, truthfulness, accuracy and completeness of information disclosure; Communicate with investors through investor conference call, fax, e-mail and interactive platform for investor relations, and receive on-site investigation of investors, so as to establish a good interactive relationship.

The company attaches great importance to the prevention of insider trading, and completes the registration management of insider information and the prevention of insider trading. Give warnings and education to directors, supervisors, senior managers and relevant employees of the company on a regular basis to prohibit insider trading, and urge directors, supervisors, senior managers and relevant insiders to strictly fulfill their confidentiality obligations and strictly abide by the regulations on stock trading.

Major changes in the company’s operation during the reporting period, as well as matters that have a significant impact on the company’s operation during the reporting period and are expected to have a significant impact in the future.

Third, possible risks

(A) operational risks

1. The risk that the expansion of the wafer factory is less than expected.

The scale of capacity investment in downstream fabs determines the market space of semiconductor special equipment. The expansion investment of the wafer factory has a certain periodicity. If the investment intensity of the downstream fabs decreases, the company will face a decline in market demand, which will adversely affect the company’s operating performance.

Under the background of localization of semiconductor equipment, the company will continuously strengthen its product market competitiveness, improve the trust of existing customers and continuously expand new customers through continuous research and development; The company will always pay attention to the development stage of the semiconductor industry cycle, coordinate all aspects of the company’s purchase, production and sales according to market conditions, and maintain the coordination between the company’s business activities and the industry cycle; At the same time, the company will always ensure that the cash flow is reasonable and sufficient to avoid the company’s operation in the downturn of the industry.

2. Market competition risk

At present, the company’s competitors are mainly internationally renowned semiconductor equipment manufacturers. Compared with Chinese mainland’s semiconductor special equipment enterprises, the international giants have the first-Mover advantage of clients, and the company’s comprehensive competitiveness is in a weak position and its market share is low. In addition, domestic semiconductor equipment manufacturers may enter each other’s business fields and develop similar products. The company faces double competition from international giants and potential new domestic entrants. If the company cannot effectively cope with the market competition environment, its industry position, market share and operating performance will be adversely affected.

At present, the company is the only manufacturer of integrated circuit PECVD equipment and SACVD equipment for industrial application in China. The company will continue to pay attention to the development of foreign competitors, shorten the technology gap with foreign manufacturers through continuous and effective R&D investment, and at the same time pay close attention to the domestic competition pattern to continuously enhance the core competitiveness of products; The company will always pay attention to the competitive situation of the industry, set the direction of research and development scientifically and reasonably, speed up the progress of research and development, and build a higher barrier to entry into the industry; At the same time, the company will also maintain closer cooperation with customers to achieve common growth with downstream customers.

3. Risk of long product acceptance period

The technical parameters of thin films deposited by thin film deposition equipment directly affect the performance of chips. In production, it is not only necessary to detect the film after it is formed

The performance indexes such as thickness, uniformity, optical coefficient, mechanical stress and granularity need to be completed in the wafer production process and chip sealing.

After installation, the reliability and life cycle of the final chip product are tested to measure whether the thin film deposition equipment finally meets the technical standards.

Therefore, the verification time required by the wafer factory for thin film deposition equipment may be longer than other semiconductor special equipment. If affected by some factors, the acceptance period of the company’s products will be extended, the company’s income confirmation and collection will be delayed, which will increase the company’s financial pressure and affect the company’s financial situation.

With the gradual expansion of the application scale of the company’s integrated circuit manufacturing production line, the company’s product technology is becoming more and more mature, and under the efficient and stable cooperation mechanism with customers, the product verification cycle is gradually shortened. The follow-up company will continue to pay attention to the company’s product acceptance and payment, and ensure the sustained and healthy development of the company’s operations.

4. The loss of technical personnel and the risk that high-end technical personnel cannot be continuously introduced.

Semiconductor equipment is a typical technology-intensive industry. In recent years, the domestic semiconductor special equipment market and wafer manufacturing demand are increasing, the competition for talents in the industry is becoming increasingly fierce, and there is a serious shortage of professional and technical talents. If the company can’t continue to provide better salary and development platform for technical talents and attract high-end technical talents from all over the world, it will face the situation of loss of technical talents and insufficient reserves, which may lead to insufficient innovation ability of the company.

The company provides R&D personnel with competitive salary and benefits in the market, continuously improves the performance evaluation and assessment promotion mechanism, and realizes the long-term common development of employees and the company. During the reporting period, there was no loss of core technicians, which ensured the stability of the core R&D team.

5. Risk of technological innovation

With the development and iteration of technology in semiconductor industry, the demand of downstream customers for thin film deposition equipment and performance also changes. Therefore, the company needs to maintain a high R&D investment and maintain the core competitiveness and advanced level of its products. If the company fails to accurately understand the requirements of downstream customers’ production line equipment and process technology evolution in the future, or the technological innovation products cannot meet the needs of customers, it may lead to the company’s equipment failing to meet the manufacturing needs of downstream production lines, which may adversely affect the company’s operating performance.

The company has established a scientific R&D system, with technical innovation closely following the market demand, and the R&D project is guided by customer demand, and always keeps continuous and effective communication with customers, so as to avoid possible losses caused by technical R&D failure.

(B) Financial risks

1. Risk of changes in government subsidy policies

During the reporting period, the government subsidies received by the company mainly supported the company’s R&D investment. In the future, if the government departments’ policy support for the company’s industry is weakened, or other subsidy policies are adversely changed, the amount of government subsidies obtained by the company will be reduced, and the company will need to invest more self-raised funds for research and development, which will affect the company’s cash flow. In addition, the reduction of government subsidies will also have a certain adverse impact on the company’s operating performance.

The company will continue to expand its business scale and improve its profitability, so as to gradually reduce its dependence on government subsidies.

2. The risk of unsustainable profitability

During the reporting period, the company’s net profit attributable to shareholders of listed companies was 108,122,700 yuan, and the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 49,150,300 yuan, turning losses into profits compared with the same period of last year. However, the company needs to maintain a large amount of investment in future R&D activities. If the progress of the company’s R&D projects or the sales of major products are less than expected, the company may have a performance that is less than expected, and there is a risk of unsustainable profitability.

Guided by market demand, the company will continue to enrich its product categories, optimize its product structure, enhance its core competitiveness, and continuously expand its market scale, so as to ensure its operating performance and enhance its profitability.

(C) Macro-environmental risks

1. The risk of increasing international trade friction affecting the safety of the company’s supply chain

In recent years, international trade friction has been constant, and Sino-US trade friction has aggravated the instability of global supply chain. At present, some parts of the company still need to be purchased from foreign suppliers. If the international trade friction intensifies further, the above-mentioned foreign suppliers may be affected by relevant policies to reduce or stop supplying parts to the company, thus affecting the company’s product production capacity, production schedule and delivery time, and reducing the company’s market competitiveness.

Companies and suppliers actively carry out deeper and broader cooperation, adopt a global and multi-source supply strategy, and build a stable cooperation channel to strengthen their own supply chain security and reduce the risks brought by the instability of the international industrial chain.

2. COVID-19 epidemic risk

At present, the epidemic situation in COVID-19 is still spreading around the world, and China is under great pressure to prevent and control the epidemic situation. If a large-scale epidemic breaks out in the place where the company operates, it will adversely affect the company’s production, sales and delivery. In addition, the spread of the epidemic may affect the healthy development of the upstream and downstream of the industry to a certain extent, which may adversely affect the production and operation of the company’s raw material supply and product transportation.

The company attaches great importance to the prevention and control of epidemic situation, always pays attention to the epidemic situation, and continuously improves the production and operation management mechanism under the situation of normalized epidemic situation. During the reporting period, the COVID-19 epidemic did not have a substantial impact on the company’s business.

Iv. analysis of core competitiveness during the reporting period

(A) analysis of core competitiveness

The company is committed to the research and development and production of world-leading semiconductor thin film equipment, and always insists on independent innovation to continuously provide competitive products for the semiconductor industry and customers. The company has established an innovative management system, and has formed competitive advantages in R&D team, technology accumulation and R&D platform, market expansion and after-sales service, which are embodied as follows:

1. It has rich technical reserves and international advanced core technology advantages.

Since its establishment, the company has adhered to independent innovation, formed a series of original designs and built a perfect intellectual property system. By the end of the reporting period, the company had obtained 187 authorized patents, including 107 invention patents.

The company has successively undertaken seven major national special projects/projects, and has developed PECVD, ALD and SACVD equipment supporting different process models, accumulated a number of core technologies for research and development and industrialization in the field of semiconductor thin film deposition equipment, and built a research and development platform with the ability to extend the development of equipment types and process models.

Facing the actual demand of domestic semiconductor manufacturing industry and the evolution rhythm of production line, the company has reserved advanced dielectric material technology thin film deposition technology below 28nm in the field of logic circuit application, 3DNAND and DRAM dielectric thin film deposition technology in the field of memory chips, and dielectric thin film deposition technology needed in the field of advanced packaging, such as TSV, 2.5D-IC and 3D-IC integration. In the future, the company will insist on high-intensity R&D investment, continuously upgrade and optimize existing equipment and processes, and constantly introduce new technologies and equipment for future development needs.

2. Excellent technical research and development and management team advantages.

The company has built an international and professional research and development and management team of semiconductor thin film deposition equipment technology. The founding team of the company takes returned overseas experts as the core, based on core technology research and development, actively introduces overseas high-level talents and independently trains local scientific research teams.

The company’s international and professional senior management team and the incentive system of full shareholding have attracted a large number of experienced domestic and foreign semiconductor equipment industry experts to join the company and made outstanding contributions in machine design, process design and software design. Since its establishment, the company has cultivated its own local research team. With the successful research and development of many products, the company’s local research team has grown into the backbone of the company’s technology research and development. By the end of the reporting period, the company had 296 R&D personnel, accounting for 43.72% of the company’s total employees. The company’s R&D technical team has a reasonable structure, clear division of labor, profound professional knowledge and rich experience in production line verification, which is the cornerstone of the company’s technical strength and guarantees the market competitiveness of its products. During the reporting period, the company’s core technical team was stable and there were no major adverse changes.

3. Leading position in the industry and rich advantages in customer resources.

With the vision of establishing "the world’s leading thin film equipment company", the company has become a leading enterprise in the domestic semiconductor equipment industry through the accumulation and rapid development in the field of thin film deposition equipment, a semiconductor core equipment subdivision.

The company has formed a relatively stable cooperative relationship with domestic semiconductor industry enterprises. The company’s main products PECVD, ALD and SACVD equipment have been sent to the production lines of major integrated circuit fabs in China in batches. In addition, the company actively pays attention to the international market demand and explores the international market in a timely manner.

4. Stable supply chain and low operating cost advantage.

The company has established a perfect supply chain management system, absorbed and accumulated global supply chain resources, established strategic cooperative relations with key suppliers, and built a stable supply chain structure. Through periodic evaluation and examination of suppliers, suppliers are encouraged to improve product quality, delivery time and cost control, so as to improve the competitiveness of enterprises. Based on collaboration, the company interacts with suppliers in real time to jointly carry out agile collaborative product innovation and maintain a good and stable cooperative relationship.

The company’s main competitors are located in the United States and Japan, and the cost of serving customers in Chinese mainland is high. The company’s R&D and production are mainly located in Chinese mainland, which has a geographical advantage. In terms of product design, the company works closely with suppliers to make products modular and easy to maintain, thus reducing the company’s raw material procurement costs. With the continuous maturity of local suppliers, the company has been given more purchasing options. Therefore, compared with its main competitors, the company has certain advantages in operating costs, and with the continuous improvement of production capacity, the advantage of cost reduction will be more obvious.

5. Provide customized products and efficient after-sales service advantages.

The company’s rapid response ability to the specific process materials and specific manufacturing processes put forward by customers can meet the needs of customized equipment in customer production lines in time. This is extremely important for local customers in China to rapidly expand their production capacity in recent years, thus establishing and consolidating a stable cooperative relationship with customers. The production base of the company’s main customers is located in Chinese mainland. Compared with international competitors, the company’s top management and technical team are closer to the main customers, and can provide efficient and timely technical support and after-sales service to ensure and meet customer needs in time.

　　CCTV News:On May 9, 10 and 11, the "International Critical Review" of the Central Radio and Television General Station was continuously published entitled "Talking about fighting may become the normal state of Sino-US economic and trade friction.》《The attempt to use the Taiwan Province issue to contain China’s adventure is bound to be a dead end.》《Tariff stick harms others and harms oneself.》《The key to solving Sino-US economic and trade frictions lies in taking care of each other’s concerns."and other four articles on Sino-US economic and trade frictions. Many overseas media and websites have been forwarded one after another.

　　From 9 to 12 May, European Times German website, British Al Araby TV (British Al Araby TV), Italian Radio We website (facebook account, twitter account), German Tagesschau 24 (German Daily News 24 TV), German-Chinese Report German website, Russian newspaper website, ORF2 Bundesland, Austria (Channel 2 of Austrian Broadcasting Corporation), Rainbow FM website in Lisbon, Portugal, Czech NovaTV Czech HD (Czech Nova TV), Czech Prima TV (Czech Prima TV), Slovak TV Markiza (Slovak Makisa TV), Turkish Economic Observation Network, Albanian National Radio and Television website, Japan’s Record China website, Japan’s Niconico website, Japan’s Oricon website, Japan’s NewsCollect website, and Korea’s OBS (Korea’s Jingren TV Station)., India’s Daily Morning News website, Iran’s instant messaging network, Iranian people’s road network, Kazakhstan’s "Industry News" website, Pakistan-China Friendship Network, Jordan Global Radio facebook account, Nepal’s Capital FM92.4 urban FM website, Myanmar opinion leader media facebook account, Brazil’s Rio headline radio station website, Brazil’s Sao Paulo World Radio Station website, Nigeria’s "Leader", Dozens of overseas media, such as Chinese PT portal, Chinese headline APP, Portuguese New Newspaper APP(facebook account, twitter account), Nordic Times website, European Union Chinese website, Africa Times website, West Africa online website, Japanese Chinese business website, Hong Kong Commercial Daily website and so on, have widely forwarded it. Hong Kong Ta Kung Pao and Wen Wei Po also published related articles.

　　The contents of "International Sharp Review: Talking about Fighting, Maybe Becoming the Normal State of Sino-US Economic and Trade Friction" are as follows:

　　The Office of the U.S. Trade Representative announced on Wednesday (8th) that it plans to raise the tariff on 200 billion U.S. dollars of goods exported from China to the United States from 10% to 25% this Friday (10th). In this regard, China responded quickly, pointing out that escalating trade friction is not in the interests of the two peoples and the people of the world. China deeply regrets this. If the US tariff measures are implemented, China will have to take necessary countermeasures.

　　Comparing the statements of China and the United States, there are two points worthy of attention:

　　First, the content of the tariff increase in the US statement is similar to the information released two days ago, but the focus is on "planning", that is, "planning". Since it is "intended" to raise tariffs, this means that the possibility of changing your mind will not be ruled out in the future.

　　Second, the Chinese side responded quickly. After about two hours, it responded briefly, but its attitude was clear and firm. The Chinese statement of more than 80 words contains three meanings: first, it points out that the negative impact of the US move is "not in the interests of the two peoples and the people of the world"; Then it shows China’s attitude: "I deeply regret"; Subsequently, the Chinese side showed that the action "will have to take necessary countermeasures", of course, this premise is "if the US tariff measures are put into practice".

　　On the eve of the eleventh round of high-level economic and trade consultations between China and the United States, the two sides issued the above statement, which is intriguing. The United States has obvious intention to pressure the asking price, while China has responded quickly and calmly, which shows that China is well prepared and reflects its consistent principled position, namely: talk, the door is open; Fight, fight to the end.

　　From this, people should see that talking about fighting and fighting while talking may have become the mode and normal state for China and the United States to solve economic and trade frictions.

　　Since February last year, Sino-US economic and trade consultations have made positive progress, but there have been many repetitions in the middle. This time, before the two sides started talking, the US suddenly announced that it would upgrade tariffs. As a spokesman for China’s Foreign Ministry said, similar situations have occurred many times before. China has long been accustomed to it, so it will naturally face it calmly. When it sees a move, it will talk about it, and if it is countered, it will be countered.

　　In fact, when announcing the tariff escalation, the US side also indicated that there is still a chance for the two sides to reach a historic agreement, and said that the two sides are preparing for the meeting between the two heads of state after the agreement is reached. Behind this seemingly contradictory move shows that China and the United States are constantly adjusting their contacts by talking about the mode and normality of solving economic and trade frictions, so as to narrow their differences and expand their consensus.

　　Against this background, it is not difficult for people to understand why the Political Bureau of the Communist Party of China (CPC) Central Committee, Vice Premier the State Council and Liu He, the Chinese leader of the China-US comprehensive economic dialogue, decided to go to the United States on invitation to attend the 11th round of China-US high-level economic and trade consultations from 9th to 10th. It’s not that China is afraid, or even forced to make concessions. It’s that China has long understood and adapted to the normal situation of settling economic and trade frictions between China and the United States, so it can grasp the general direction of the consultation process from a higher level instead of being disturbed by one thing at a time.

　　It is China’s consistent principled position to resolve contradictions and differences through negotiations. Ten rounds of high-level economic and trade consultations between China and the United States have passed, and the two sides have made substantial progress in trade procurement, structural issues, implementation mechanisms, etc. It is not easy and needs to be doubly cherished, but at the same time there are still problems that need further discussion. Therefore, at the end of the tenth round of high-level consultations, the two sides agreed to hold the eleventh round of consultations in Washington this week to continue the discussion. Although the United States has not played its cards according to common sense, which has caused great confusion to this round of consultations, China cannot be affected by this. Going to the United States for consultations as planned is China’s respect for the negotiation rules and the consensus reached by the two sides in the past 16 months.

　　Chinese pays attention to reason rather than willfulness. China and the United States have different stages of economic development, and their economic structures and systems are also very different. It is normal for the two sides to have frictions in economic and trade, and it is not surprising that various twists and turns will occur during the consultation.

　　Now, the United States says it wants to upgrade tariffs, which shows that it has become a little anxious now. Although the United States has repeatedly said that China is paying the US tariff, US lawmakers do not agree with this statement. For example, Senator James Lankford, a Republican, said that American importers have paid more than $16 billion in tariffs to the government, and American companies have paid the tariffs instead of China exporters.

　　In contrast, China has a clear understanding of the long-term, complex and arduous nature of Sino-US economic and trade issues, and will not deviate from the original track because of a temporary incident. Past experience has proved that hard suppression can’t solve the problem at all, and eventually we have to return to the negotiating table. Moreover, the more differences there are, the more it is necessary to communicate face to face. China’s planned visit to the United States for consultations is to solve each other’s concerns and push the negotiations back to a rational track.

　　More importantly, China has always been a responsible big country. The supreme leader of China and president has repeatedly stressed that the relationship between major powers is related to global strategic stability, and China and the United States share extensive common interests and shoulder important responsibilities in safeguarding world peace and stability and promoting global development and prosperity. Over the past year or so, Sino-US economic and trade frictions have not only harmed the interests of the two countries, but also dragged down global economic growth. The latest World Economic Outlook report released by the International Monetary Fund has lowered the global economic growth rate by 0.2% and 0.1% to 3.5% and 3.6% respectively this year and next.

　　Whenever there is a positive signal from Sino-US economic and trade negotiations, the stock markets of China, the United States and the world will be boosted, and whenever the negotiations are frustrated, the stock market will inevitably oscillate. This reflects that if China and the United States shake hands and make peace, the whole world will benefit; The breakdown of Sino-US negotiations is bound to drag down the world.

　　In the face of US tariff pressure, China still keeps its appointment calmly, which is not only responsible for China and the United States and their peoples, but also safeguarding the development interests of people all over the world and providing more stability and predictability for the recovery of the world economy.

　　Soon, the eleventh round of high-level economic and trade consultations between China and the United States will be held in Washington. China will, as always, do its utmost to push the consultations back to the right track with the greatest sincerity. However, negotiations are a matter for both sides, and the United States needs to move in the opposite direction in order to control differences and expand cooperation. The United States has long known the bottom line of China, that is, China is unwilling to fight a trade war, but it is not afraid to fight, and it has to fight if necessary; China is also willing to solve the differences between the two sides through cooperation, but the bottom line of cooperation is not to harm the core interests of China countries and the fundamental interests of the people.

　　Regardless of the outcome of the consultations in the next two days, China will calmly face all possibilities, continue to do a good job in China and go its own way. In the past 16 months, China’s economy, society and people’s psychology have already stood the test in the escalating tariff war of the United States, and its ability to withstand pressure has been greatly enhanced. Moreover, there are more positive signals in favor of China now. China has the confidence and ability to withstand any storm, and become more tenacious in the fight against the storm, and achieve high-quality development with greater reform and higher level of opening up, creating more opportunities for development cooperation for the world.

　　Many overseas media forwarded this article:　

"Russian newspaper" website forwarded on May 9

Japan Record China website forwarded on May 9.

Hong Kong Ta Kung Pao was published on May 10th.

Hong Kong Wen Wei Po was published on May 10th.

　

　　The International Critical Review: An attempt to use the Taiwan Province issue to contain China’s adventure is bound to be a dead end.

　　On Tuesday (7th), the US Federal House of Representatives passed the so-called "Taiwan Province Guarantee Act of 2019" and "Reaffirmation of US Taiwan and its implementation of ‘ Taiwan relations act ’ Commitment "resolution, which is an extremely dangerous political action by the United States to use the Taiwan Province issue to rudely interfere in China’s internal affairs and curb the peaceful development of China, once again exposes the extremely bad behavior of some American forces playing politics. If the United States goes its own way, it will seriously damage Sino-US cooperation in important areas and seriously endanger peace and stability in the Taiwan Strait. In this regard, China resolutely opposes and has made solemn representations to the US.

　　On January 1, 1979, during the term of President Carter, China and the United States formally established diplomatic relations at the ambassadorial level. On the occasion of the 40th anniversary of the establishment of diplomatic relations between China and the United States this year, Mr. Carter wrote an article in Washington post, warning that any misjudgment, miscalculation and non-compliance with carefully formulated rules of conduct by both sides would lead to "worldwide disaster" when the relationship between the two countries entered a sensitive moment. Politicians in the American Congress must know that any adventure that attempts to use the Taiwan Province issue to contain China will be a dead end. Because: it has made three serious mistakes:

　　One of the mistakes: completely damaged the foundation of the development of relations between China and the United States. In today’s world, exchanges between countries must abide by certain principles and norms, which is the basis for maintaining, stabilizing and upgrading bilateral relations. As the world’s two largest economies and important political forces on the international stage, the more stable and solid the foundation of bilateral relations, the more stable and predictable it will be for the world. This basis was clearly defined in the three joint communiques on the establishment of diplomatic relations between China and the United States, that is, there is only one China in the world, the mainland and Taiwan Province belong to the same China, and People’s Republic of China (PRC) is the sole legal government of China. The U.S. House of Representatives upgraded the former "Taiwan Relations Act" to the "Taiwan Province Guarantee Act" in an attempt to promote military cooperation with Taiwan Province only for sovereign countries, which completely deviated from the one-China principle and seriously undermined the basic norms of international law and international obligations. If this foundation is lost, what can support the development of Sino-US relations? !

　　Mistake 2: Trying to test China’s bottom line by playing "Taiwan Province". Whenever there are twists and turns or difficulties in Sino-US relations, the Taiwan Province issue will always be put on the table by the United States as a bargaining chip to negotiate, coerce and contain China. This has become a common tactic of some politicians in the United States. It is understandable that the two countries sitting at the negotiating table hold some bargaining chips and strive for the maximization of interests for their respective countries. But the Taiwan Province issue has never been, and will never be, a bargaining chip in resolving Sino-US relations. Because the Taiwan Province issue is an internal affair of China, which concerns the core interests of China and the national dignity and feelings of 1.4 billion Chinese. No foreign forces can interfere in it, let alone trade it. What can be told to the United States is that there is no future in trying to test the bottom line with the Taiwan Province issue.

　　Mistake 3: It has caused turmoil in the Taiwan Strait and endangered regional peace and stability. In 2018, Democratic Progressive Party, with the concept of "Taiwan independence", suffered a crushing defeat in the "Nine in One" election in Taiwan Province, and lost momentum. Next year, the prospect of the leadership election in Taiwan Province is bleak. At this sensitive moment, the United States offered the "Taiwan Province card" in an attempt to give the "Taiwan independence" forces a lifeline. Some American politicians should carefully read Mr Carter’s article in Washington post and realize that if the Taiwan Province issue is not handled properly, it may escalate into a regional conflict and bring disaster to the world. This statement is not alarmist.

　　In April this year, the current US President Trump called Mr. Carter and asked the former president how to deal with China. It is reported that one of Carter’s suggestions is "Don’t fight". If American politicians try to break through China’s last red line on the Taiwan Province issue, including sending warships to Taiwan Province, it will be the charge for China to unify Taiwan Province.

　　The supreme leader of president, China, has repeatedly stressed that China is committed to promoting coordination and cooperation among major powers, expecting them to live in harmony without conflict, confrontation, mutual respect and win-win cooperation. As one of the most important bilateral relations in the world, Sino-US relations are moving forward along the tone of coordination, cooperation and stability, which cannot and should not be changed. Some American politicians should not underestimate Chinese’s determination on the Taiwan Province issue.

　　Many overseas media forwarded this article:

　　"Russian newspaper" website forwarded on May 9

"German-Chinese Report" was forwarded by German website on May 9.

The website of Albanian National Radio and Television Station was forwarded on May 9.

The website of China Radio Station in Rio, Brazil was forwarded on May 9.

European Union Chinese Network forwarded on May 9.

The Portuguese news APP(facebook account, twitter account) was forwarded on May 9.

　

　　The contents of "International Sharp Review: Tariff Sticks Harm Others and Harm Yourself" are as follows:

　　At 0: 01 Washington time on the 10th (12: 01 Beijing time on the 10th), the US tariff on China’s 200 billion US dollars of goods exported to the US was raised from 10% to 25%. In response, China issued a statement at 12: 03 Beijing time on the 10th, almost simultaneously announcing that it had to take necessary countermeasures.

　　The Sino-US trade war has escalated again, and this result is regrettable. The reason lies in the fact that the United States ignores China’s sincere attitude and actions, and always pursues "America first", asking exorbitant prices and exerting extreme pressure, which fundamentally violates the negotiation principles of mutual respect, equality and mutual benefit, thus leading to the escalation of friction.

　　Negotiation is a matter for both sides. China has shown its utmost sincerity and done its best with practical actions, but it also needs the US to move in the opposite direction. In fact, Sino-US economic and trade consultations have been going on for more than a year, and China has long learned from the US’s manner. The US should also be well aware of China’s principles and positions, that is, China is unwilling to fight a trade war, but it is not afraid to fight it, and it has to fight if necessary; China is willing to solve the economic and trade differences and frictions between the two sides through cooperation, but such cooperation is principled, that is, it must not harm the core interests of China countries and the fundamental interests of the people.

　　Today, people must see that when the United States has repeatedly declared that the United States and China have reached a historic agreement, it suddenly insists on escalating tariffs, which is a flagrant violation of its international obligations in the WTO, a blatant challenge to multilateral trade rules, and will further harm the interests of China and the United States and the world, and has been strongly opposed by people around the world, including the American people. Tom Donohue, president of the American Chamber of Commerce, made it clear that he did not support launching a trade war by imposing tariffs, because it was American families and American enterprises who paid tariffs, not foreigners. A lobbying organization representing more than 150 trade associations in the United States-"tariffs hurt the hinterland of the United States" also issued a statement, pointing out that raising tariffs would damage nearly 1 million jobs in the United States and punish American farmers, enterprises and consumers.

　　The United States once again raised the tariff stick in an attempt to stop the development of China, but it will not succeed. People have seen that over the past year or so, China has responded appropriately, and its economic, social and public psychological resistance has been greatly enhanced. Now there are more positive signals in favor of China in all aspects, and China will respond more calmly, with more confidence and ability to withstand the test of storms. China will create more development opportunities for the world by running its own business well and promoting high-quality economic development with greater reform and higher level of opening up.

　　Many overseas media forwarded this article:

Italian Radio We website (facebook account, twitter account) forwarded on May 10th.

　　Turkish economic observation network forwarded on May 10

　Chinese PT portal website forwarded on May 10th.

Japan Chinese Business Network forwarded on May 10th.

　　West Africa Online Network forwarded on May 10th.

　　Hong Kong Ta Kung Pao was published on May 11th.　

Hong Kong Wen Wei Po was published on May 11th.

　

　　The contents of "International Critical Review: The Key to Solving Sino-US Economic and Trade Friction is to Take Care of Each Other’s Concerns" are as follows:

　　The 11th round of China-US high-level economic and trade consultations ended in Washington on Friday (10th) local time. In an interview after the consultation, Liu He, member of the Political Bureau of the Communist Party of China (CPC) Central Committee, Vice Premier the State Council and Chinese leader of the China-US comprehensive economic dialogue, said that the two sides had good communication and cooperation, and the negotiations did not break down, but on the contrary, this was just a normal minor twist in the negotiations between the two countries, which was inevitable. China was cautiously optimistic about the future of the negotiations. He also revealed that the economic and trade teams of the two sides agreed to meet in Beijing soon to continue communication and promote consultations.

　　Earlier, at 0: 01 Washington time, the United States raised the tariff on $200 billion of goods exported from China to the United States from 10% to 25%. In response, China issued a statement two minutes later, almost simultaneously announcing that necessary countermeasures had to be taken.

　　This result is not surprising. Because, since February last year, Sino-US economic and trade consultations have been held for eleven rounds. Although important progress has been made, it has been repeated several times. Talking about fighting may have become the normal state of Sino-US economic and trade friction. Before this round of negotiations, the United States said it would upgrade tariffs, which led to concerns that Sino-US negotiations would break down. Under such pressure, the Chinese delegation still went to the United States to participate in the eleventh round of consultations as scheduled, which itself showed the greatest sincerity in solving the problem and was highly responsible for the interests of the two peoples and the people of the world.

　　However, the US accused China of trying to renegotiate some contents of the agreement, trying to blame China for the unsuccessful negotiations, which was obviously unfair.

　　On the one hand, negotiation is a process of exchanging opinions, solving problems and reaching consensus. It is normal for both sides to have different views, and it is normal for them to make changes before reaching an agreement. Therefore, it is even more necessary for the two sides to further discuss to resolve their differences and expand their consensus, instead of using the differences and changes in the negotiation process as the reasons for increasing tariffs. This is obviously an overreaction, wrong prescription, wrong force and artificial obstacles to the negotiation process.

　　On the other hand, the United States accused China of "retrogression" and labeled China as "abandoning" and "breaking faith". But so far, what China has "promised" is all the words of the United States, and I am afraid there are many elements of China’s "promised". All along, the US side has been talking about whether China meets its economic and trade concerns, but has kept silent about whether it meets China’s concerns, which violates the negotiation principles of mutual respect, equality and mutual benefit, and this is also an important reason for the failure to make progress in this round of negotiations.

　　China has its own core concerns about Sino-US economic and trade consultations, and it cannot make concessions on these issues of principle. The first is to cancel all the additional tariffs and restore normal bilateral trade. Tariffs are the starting point of Sino-US trade disputes. If an agreement is reached, of course, all tariffs must be abolished. In today’s highly globalized industrial chain, increasing tariffs will inevitably have an impact on the economies of China and the United States, and will also hurt all links in the industrial chain. Over the past year or so, the negative impact of Sino-US economic and trade frictions has proved that there is no winner in the trade war, and adding tariffs is not the solution to the problem. At present, the global voice against imposing tariffs, including the American people, is getting stronger and stronger. The United States should respect China’s demands and take into account the interests of people all over the world.

　　On the issue of trade procurement, the United States has repeatedly asked China to expand imports from the United States, and even asked China to commit a specific amount. However, China’s expansion of imports should be based on meeting the needs of domestic people for a better life and promoting high-quality economic development. The figures of trade procurement should not only be in line with reality, but also be globally oriented. Any product that is competitive will be welcomed by consumers in China, instead of "buying hard and selling hard".

　　There is also the text of the agreement, which should include both American demands and Chinese claims, reflecting the balance of the agreement. Moreover, the expression of the text should be accepted by the people in China, and it will not damage the sovereignty and dignity of the country. Only such an agreement can be truly implemented.

　　As the United States insisted on increasing tariffs, China was forced to counter it, and the Sino-US trade war escalated again. This situation makes China regret, but it is also calm. Over the past year or so, under the pressure of the US tariff escalation, China’s economy has been affected to some extent, but it has been proved that the impact is completely controllable and affordable. In the first quarter of this year, China’s GDP increased by 6.4% year-on-year. In the first four months, the total value of import and export of goods increased by 4.3%, and the main indicators of economic operation such as employment, prices and income were generally better than expected. The International Monetary Fund has raised China’s economic growth forecast by 0.1% to 6.3%, and China has become the only country in the world that has raised its economic growth forecast. Warren Buffett, a famous American investor, recently said that investing in China is ideal, and "there may be some big deployment in the next 15 years".

　　This information shows that over the past year or so, China has taken appropriate measures to deal with external shocks, which has enhanced its economic resilience, market potential and confidence in investment and consumption. In this regard, Liu He confidently stated that China’s policy tools are sufficient, and China’s economy will maintain a good momentum of steady and healthy development. This means that in the future, China will respond to external challenges more calmly, promote high-quality economic development in accordance with the established deployment, and meet people’s needs for a better life.

　　It is noteworthy that although China and the United States still have differences on core concerns, they still agree to continue to maintain communication. This shows that after all kinds of twists and turns, both sides have a better understanding of each other’s bottom line and principles, and both have a strong will to continue negotiations to solve the problem. After all, economic and trade cooperation is the ballast stone and propeller of Sino-US relations, and both sides have benefited a lot from it.

　　In the future, China will continue to communicate with the United States with the utmost sincerity and efforts, strive to narrow differences, expand consensus and push forward consultations. However, this consultation should respect each other’s core interests and major concerns and embody the principle of equality and mutual benefit. Only in this way can China-US economic and trade consultations survive the final stage of the marathon and the "darkness before dawn", and then explore a mode of managing differences and expanding consensus, and promote the construction of Sino-US relations based on coordination, cooperation and stability.

　　Many overseas media forwarded this article:　

Germany Tagesschau 24 (German Daily News 24 TV) quoted on May 11th.

Austrian ORF2 Bundesland (Austrian Broadcasting Corporation Channel 2) quoted on May 11th.

Czech NovaTV Czech HD (Czech Nova TV) quoted on May 11th.

　Slovak TV Markiza (Slovak Makisa TV) quoted on May 11

British Al Araby TV (British Al Araby TV) quoted on May 12

　South Korea OBS (Korea Jingren TV Station) quoted on May 12

Prima Czech (Prima Czech TV) quoted on May 11

The website of Nordic Times was forwarded on May 11th.

Japan NewsCollect website forwarded on May 11th.

　Pakistan-China Friendship Network forwarded on May 11th.

Facebook account of Myanmar opinion leader media was forwarded on May 11th.

　Hong Kong Ta Kung Pao was published on May 12th.

Hong Kong Wen Wei Po was published on May 12th.

　　[car home News] A few days ago, a Tesla China owner asked Musk on social media, "I expect Tesla FSD (fully autonomous driving) to enter China as soon as possible. I don’t know when it will be realized. When can HW3.0 system model images in 3D? When can the new parking assist be pushed to the owner of Tesla HW3.0 in China? "In this regard, Musk replied that "it may be realized soon.".At the same time, we can see that Tesla’s website shows that Tesla has reduced the price of fully automatic driving (FSD) package from $12,000 to $8,000 in the United States.

　　Since March this year, Tesla has started to deploy its software update to promote the latest FSD V12.3 beta version, which was integrated into the software update of 2023.44.30.25. Tesla CEO elon musk bluntly said: "This is a major release, and it can be said that it should be called V13."

　　Since its first launch on October 20, 2020, FSD has only been available in Beta in North America. Tesla released new software updates through beta to verify its latest autonomous driving technology and improve performance. At present, the system can’t realize full automatic driving, and it needs the supervision of the driver.

　　Last November, it was reported that Tesla FSD Beta was about to enter China. Tesla China official website updated the owner’s manual of China with FSD Beta, which indicates that FSD will soon land in China. Taking the new Tesla Model 3 as an example, it costs 64,000 yuan to install the FSD. After the installation, it can realize the functions of recognizing and responding to traffic lights and stop signs, and automatically assisting driving in urban streets.

　　Tesla has made a lot of preparations before landing in FSD in China. In 2021, a data center was established in Shanghai. All data generated by China business, including production data, sales data, service data and charging data, are completely stored in China to meet regulatory requirements. In addition, Tesla set up an FSD operation team and a data labeling team in Shanghai, and sent engineers from this department to do training. However, Tesla China once responded to the domestic media that "it is really in progress at present". (Compile/car home Wang Yin)

　　First, the overall design

　　Activity name: China (Henan) Pilot Free Trade Zone International High-end Management Talent Exchange and Cooperation Forum (hereinafter referred to as "Free Trade Zone High-end Talent Forum").

　　Theme of the event: Carry forward the spirit of Henan merchants in the new era and create a high-quality open highland.

　　Activity time: October 26th from 14: 30 to 18: 00.

　　Venue: Hall 3, Zhongyuan Grand Ballroom, Sheraton Meisheng Hotel

　　Activity scale: 200 people

　　Organizer: Henan Provincial Department of Commerce and Henan Pilot Free Trade Zone Work Office.

　　Co-organizer: Administrative Committee of Zhengzhou, Kaifeng and Luoyang in Henan Pilot Free Trade Zone

　　Second, the participants

　　Provincial government leaders; Responsible comrades of leading group member units; Director, deputy director and relevant personnel of Zhengzhou, Kaifeng and Luoyang administrative committees of Henan Pilot Free Trade Zone; Representatives of district enterprises; News media.

　　Invite well-known Henan entrepreneurs and senior executives of financial institutions at home and abroad, representatives of other influential enterprises and innovation and entrepreneurship projects at home and abroad, and representatives of experts, scholars and high-level talents at home and abroad to attend the meeting.

　　III. Agenda

　　Moderator: To be determined

　　The first session is from 14: 30 to 16: 00: Main Forum.

　　The first agenda: broadcast the propaganda film of Henan Pilot Free Trade Zone (10 minutes);

　　The second agenda: Speech by the leaders of Henan Province (6 minutes);

　　The third agenda: Zhang Yanming, Director of the Henan Provincial Department of Commerce, introduces the free trade zone and publishes the policy advantages of talent projects (10 minutes);

　　The fourth agenda: Introduce the policies for attracting talents (projects) and policies for attracting talents, and release the demand for key talents (projects) (24 minutes);

　　The fifth agenda: speeches by domestic and foreign experts and scholars, Henan entrepreneurs and financial executives (3, 10 minutes each);

　　Agenda 6: On-site signing (10 minutes);

　　Adjust the venue of the rostrum and place the sofa (5 minutes);

　　The second session: 16:05-18:00: Two rounds of live dialogue sessions.

　　Moderator: Chen Kaijie, member of the Party Group of the Provincial Department of Commerce and deputy director of the Free Trade Office.

　　16:05-17:00 Henan businessmen do business after their return to China.

　　17:05-18:00 Financial elites talk about free trade.

　　The third link on October 27th, 09:00-12:00.

　　Investigation and investigation in Zhengzhou area

　　Fourth, the venue design

　　The venue covers an area of 500 square meters.

　　1. The main background board is a 7X3.5 HD LED screen. The propaganda film "Welcome to Open Henan" was broadcast before the event, and the cultural and trade industry matchmaking fair in Henan Pilot Free Trade Zone was displayed during the event. When presenting and speaking, display PPT synchronously.

　　2. The podium is equipped with a podium, a desktop microphone and a wireless microphone.

　　3. The first two rows of the seats are desk-shaped, with seat tags. The first row is the provincial leaders, department leaders and important guests, and the second row is the leaders and speakers who came to the stage to promote. The third row is arranged in a theater style, with about 200 seats.

　　4. Media seats: Media seats will be set up behind the participants for the use of participating news media reporters.